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Infectious diseases continue to be a threat to millions globally – largely because of highly 
effective immune evasion mechanisms evolved in pathogens. Our work focuses on 
engineering proteins to shield selected epitopes thereby refocusing the immune response 
to other regions on the protein antigen. In the context of vaccine design, nanopatterning 
can help preferentially elicit broadly neutralizing antibodies while suppressing the response 
to epitopes that serve as immunological decoys. We have developed two approaches to 
achieve this shielding and refocusing – one referred to as “Nanopatterning” that uses site-
specifically conjugated polymeric shields and a second approach that uses engineered 
antibody fragments (Fabs) as shielding agents. For the nanopatterning approach we have 
demonstrated preferential immunosuppression of a defined epitope on green-fluorescent 
protein (GFP) as a model antigen. We then extended this nanopatterning idea to engineer 
a promising malarial antigen – Merozoite surface protein-1 (MSP1) that is unusual in 
eliciting so-called “blocking antibodies” that interfere with the neutralizing “inhibitory 
antibodies” and that even promote infection. We have nanopatterned MSP-1 to elicit 
antibodies that recognize MSP-1 from heterologous strains, differing in sequence at as 
many as 21 of 96 residues. The second approach explores the use of Fabs as shielding 
agents. Here, we have demonstrated the ability to refocus the immune response to broadly 
neutralizing epitopes of two antigens – Hemagglutinin (HA) of the Influenza virus and 
Domain III (DIII) of the Zika Virus (ZIKV) Envelope protein. We have shown that by 
either tethering the Fab to the antigen (for HA and DIII) or by using bivalent soluble Fab 
shields (for HA), the immune response can be focused on their broadly protective epitopes. 
In summary, this work explores two new approaches to achieve immunofocusing – 
 xiii 
allowing refocusing of the immune response to protein antigens. These tools should be 
broadly applicable for the design of broadly protective vaccines against pathogens such as 
malarial parasites, influenza, flaviviruses and HIV.  
 1 
CHAPTER 1. INTRODUCTION 
Our bodies combat infections from pathogens using a variety of effector cells and molecules 
that together make up the immune system. Broadly, immune responses are classified as: (i) 
innate immune responses – which are always immediately available to combat a wide range 
of pathogens, and are non-specific in nature; and (ii) adaptive immune responses – which are 
developed during the lifetime of an individual, generate an immunological memory, and can 
sometimes confer lifelong protective immunity to reinfection against the same pathogen [1]. 
The first step in this process of developing immunological memory is immune recognition – 
wherein certain immune cells, called as B lymphocytes (B cells), recognize and interact with 
the antigen (the foreign pathogen or their components) to develop an immune response 
against the pathogen [2]. B cells present B-cell receptors (BCRs) on their surface which bind 
to a region on the antigen. Once a B cell binds to an antigen, a series of downstream events 
occur, triggering the B cells to proliferate and differentiate into plasma cells, which 
ultimately produce antibodies specific to the antigen [3]. Immunity mediated by 
macromolecules such as antibodies is referred to as antibody-mediated or humoral immunity. 
The focus of the current thesis is on immunity developed via the B cell arm of the immune 
system, producing antibodies specific to certain defined regions of the antigen. Another class 
of immune cells called T lymphocytes (T cells) complement the B cells in combating the 
pathogen. A class of T cells called as Helper T cells provide signals to the antigen-stimulated 
B cells influencing the production of antibodies [4]. During the course of this immune 
response, some B cells activated by the antigen differentiate into memory B cells, providing 
long lasting immunity following exposure to infection with that pathogen later in life [1].  
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Vaccination is the deliberate stimulation of the immune response towards a pathogen known 
to cause disease. Early vaccination attempts involved using attenuated organisms with 
reduced pathogenicity (called as live-attenuated vaccines), which could still stimulate an 
immune response and protective immunity but not disease [5]. A second class of vaccines is 
based on killed organisms (called as inactivated vaccines), which addressed some of the 
safety concerns associated with live vaccines such as lethal systemic infections [6]. Evolving 
from this approach, is a class of vaccines called subunit vaccines – which use specific pieces 
or fragments of the pathogen known to be immunogenic. Subunit vaccines are based on 
purified whole surface proteins, peptide fragments, polysaccharides or capsids [7].  
A drawback of vaccines based on purified recombinant proteins or peptides is that they do 
not activate the immune system in the same way that a natural infection does [8]. These 
subunit vaccines, thus usually require the coadministration of additional components, 
referred to as adjuvants, which enhance the immunogenicity of antigens [9]. Adjuvants 
activate a class of immune cells called antigen-presenting cells (APCs) by providing ligands 
for Toll-like receptors (TLRs) and other receptors on APCs – which are the innate viral and 
bacterial sensor pathways[10]. For example, Freund’s complete adjuvant (FCA) is an oil-in-
water emulsion of killed mycobacteria comprising immunostimulatory components such as 
the complex glycolipid and other bacterial cell wall components.   
Vaccines constitute one of the most effective tools to prevent infectious diseases [11, 12]. 
However, for numerous important diseases, currently available vaccines do not provide 
broad, durable, and effective protection – largely because of highly effective immune evasion 
mechanisms in pathogens [13-16]. For instance, in several cases, immunodominant regions 
of protein antigens are highly variable in sequence and elicit narrow or even strain-specific 
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immune responses. Consequently, there is a growing need to refocus the immune response 
on the conserved and broadly neutralizing epitopes. 
The current work explores novel tools to achieve immunofocusing to engineer antigens from 
three medically highly relevant infectious diseases – Malaria, Influenza, and Zika. Malaria 
is a vector-borne parasitic tropical disease caused by Plasmodium, found in 91 countries [17]. 
Plasmodium falciparum and P. vivax are the predominant species that infect humans, with 
an estimated incidence of 219 million cases worldwide in 2017 – of which 99.7% of the cases 
were caused by P. falciparum [17]. There were an estimated 435,000 deaths from malaria 
globally in 2017-2018, with children under 5 years of age being the most vulnerable group 
[17]. The development of an effective vaccine is important to control malaria transmission, 
in addition to the existing control measures. RTS,S/A01, based on the pre-erythrocytic 
subunit of the parasite, is the only malaria vaccine that has reached phase 3 clinical trials. 
However, this vaccine induces short-lived responses [18, 19] with only modest efficacy of 
~40% [17]. It has been suggested that next generation vaccines must build on the success of 
the current pre-erythrocytic subunit vaccines, as well as explore blood-stage or transmission 
blocking immunity [20].  
Influenza viruses cause mild to severe respiratory infections and constitute a major public 
health problem. While seasonal influenza epidemics cause an estimated 250,000 to 500,000 
deaths annually worldwide [21], the “Spanish” influenza pandemic of 1918 has been 
estimated to have caused approximately 40 million deaths [22]. In the United states alone in 
the 2017-2018 season, an estimated 48.8 million people were infected with Influenza, 
resulting in an estimated 80,000 deaths [23]. Vaccines are currently the best available 
measure to control the spread of Influenza, however, the vaccine effectiveness is low 
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compared to that for other viral infections, and the resulting immunity is narrow and short-
lived [24]. The ultimate goal to combat Influenza infection by vaccination, is to design a 
“Universal” Influenza virus vaccine that induces long-lived protection against drifted 
seasonal and pandemic influenza infections.  
Zika virus (ZIKV) is a flavivirus that sparked global attention in 2015 – with a large number 
of infections in Brazil followed by outbreaks and transmission throughout the Americas, 
Africa, and other regions of the world [25]. ZIKV infection during pregnancy has been linked 
to microcephaly and other congenital neurodevelopment defects [26]. A study showed a 100-
fold increase in the incidence of microcephaly incidence from late 2015 to early 2016, 
mirroring the incidence of ZIKV infection [27]. ZIKV was also found to be associated with 
the Guillain-Barre syndrome, an inflammatory demyelinating polyneuropathy [28]. 
Moreover, the risk of disease transmission is exacerbated by the fact that ZIKV can be 
transmitted sexually. Although, no longer classified as a global emergency, ZIKV continues 
to spread geographically in areas where the competent vectors (mosquitoes from the Aedes 
genus) are present. To date, there is no approved vaccine, antiviral drug, or other modality 
to prevent or treat ZIKV – emphasizing the need for a vaccine [29]. 
Most antibodies bind to the “viral spikes” – which are basically surface proteins that assist 
the pathogen in infecting the host. These surface proteins, however, are highly variable in 
sequence. For example, the sequence of hemagglutinin (HA), a surface protein on the 
influenza virus, changes so rapidly that a different vaccine needs to be manufactured every 
year. Fig. 1 shows a cartoon of the gp120 surface protein of human-immunodeficiency virus 
(HIV) and the HA surface protein of influenza, with increasing extents of variability of the 
amino acids for these surface proteins indicated by increasing shades of purple. For a large 
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number of pathogens, the host immune response is often focused on the most variable 
epitopes. In contrast, the conserved regions of these proteins — often receptor binding sites 
or other essential functional domains – are usually poorly immunogenic and naturally 
immunosubdominant.  As a result, there have been growing efforts to engineer these antigens 
to refocus the response to their conserved broadly protective regions, using strategies 
collectively referred to as immunofocusing [30, 31]. Fig. 2 shows the structure of the trimeric 
ectodomain of influenza hemagglutinin with its globular head and stalk domain marked. The 
head domain is highly variable (marked by red residues in Fig. 2B) and immunodominant. 
 
Figure 1. Sequence variability in antigenic surface proteins. Structure of 
glycoprotein 120 (gp120) of HIV and Hemagglutinin (HA) of Influenza virus shown 
with the sequence variability of their surface residues highlighted in increasing shades 
of purple indicating the extent of variability. Figure adapted from Pancera et al., 2014 




The stem domain on the other hand is fairly conserved. The epitope for a broadly neutralizing 
stalk binding antibody is shown in blue in Fig. 2B. As a result, efforts to engineer HA to 
design a broadly protective vaccine against influenza, involve immunofocusing to the stem 
domain. Fig. 2 C illustrates various strategies to focus the response to the conserved stem 
region – indicated by a blue patch [32]. Antigenic resurfacing involves the alteration of all 
 
Figure 2. Existing methods of Immunofocusing. (A) Trimeric ectodomain structure 
of Influenza Hemagglutinin (HA) in a ribbon form. Each protomer of the trimer is 
highlighted in a different color. HA has a globular head domain and a membrane 
proximal stem domain. (B) Spacefilled structure of HA with the residues in red 
showing the variable head epitopes and the residues in blue showing an epitope for a 
broadly neutralizing stalk antibody. This target region for immunofocusing (stem 
region) is highlighted by a circle. (C) Schematics for immunofocusing strategies 




surfaces other than the desired site where the immune response needs to be focused [33]. 
However, this approach will still result in an immune response to the resurfaced residues and 
does not focus the response on the targeted regions. Immunosilencing attempts to reduce the 
immunogenicity of regions outside of the target epitope through the addition of inert moieties 
such as N-linked glycans [34, 35]. Glycosylation, however, is a blunt tool allowing limited 
control over the manipulation of the immune response. Moreover, glycans can themselves 
become as part of neutralizing epitopes. Truncation cuts out immunologically-irrelevant 
regions of the antigen leaving behind just regions of interest. This approach has been used 
successfully to design headless HAs, with a stabilized stalk-only trimer removing 
interference from head response altogether. Although, truncation is an elegant strategy to 
focus the immune response to the most relevant parts, this strategy needs significant protein 
engineering and may need to be reworked for every new antigen. Furthermore, depending on 
the structure of the antigen and the location of the epitope of interest on this antigen, a 
truncation strategy may not always be possible. 
In this work, we have developed two new strategies to address some of these limitations and 
to expand the existing toolkit of immunofocusing. First, we have developed a technique 
referred to as nanopatterning, in which the precise control over the attachment of PEG chains 
to a protein antigen provides finer control over the modulation of immunogenicity. This 
approach is in contrast to traditional methods to PEGylate proteins with a high surface 
density of PEG resulting in global immune suppression [36]. We have demonstrated the 
success of our approach using green fluorescent protein (GFP) as a model antigen and further 
extended the idea to an important malarial antigen to focus the response to its broadly 
protective epitope. This approach has been discussed in Chapter 2. Second, we have 
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developed another novel approach to immunosilencing that utilizes antibody fragments as 
shielding agents. Since the binding of an antibody fragment to its antigen is non-covalent in 
nature, our approach involves engineering these fragments as shields with enhanced binding 
to the antigen. We have developed two related approaches, one that involves tethering 
antibody fragments to the antigen and a second approach involving the design of bivalent 
antibody fragments as shields. We have demonstrated the applicability of antibody fragments 
as shielding agents in the context of HA (Chapter 3) and a Zika virus surface protein (Chapter 
4) to show their ability to suppress the immune response towards “undesirable” epitopes. 
Methods discussed in this work can be applied to antigens from other infectious diseases to 
design more effective vaccines.  
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CHAPTER 2. NANOPATTERNING PROTEIN ANTIGENS 
TO SELECTIVELY REFOCUS THE IMMUNE 
RESPONSE 
2.1 Introduction 
PEGylation of therapeutic proteins has been widely used to improve the physicochemical 
properties of therapeutic proteins and their biomedical efficacy. Several PEGylated 
products have been approved for use over the years [36]. This approach, however, has 
primarily been used to eliminate immunogenicity. Another approach to influence protein 
immunogenicity involves the modulation of glycosylation [37, 38]. The human 
immunodeficiency virus (HIV) has a dense glycan network that shields its neutralizing 
epitopes from the immune system [37, 38]. The removal or addition of glycosylation sites 
has also been used to modulate the immunogenicity of protein antigens [35, 39-42]. 
However, there are several limitations to using glycosylation for modulating the immune 
response to protein antigens. First, this post-translational modification is often vital for the 
proper folding of proteins. Second, glycans themselves can become part of neutralizing 
epitopes. For instance, in case of HIV, many broadly neutralizing antibodies directly target 
glycans or bind to epitopes partially composed of glycans [43].  Finally, glycosylation is a 
blunt tool that provides limited control over the structure of the glycans. 
Similarly, traditionally used PEGylation strategies have several limitations as far as their 
ability to modulate protein immunogenicity is concerned [44]. Firstly, a succinimide 
functionalized polyethylene glycol (PEG) moiety reacted non-specifically and randomly to 
the surface exposed amine groups has limited control over the attachment site. The 
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cysteine-maleimide chemistry, which involves incorporating a cysteine residues within the 
protein followed by reaction with a maleimide functionalized PEG, is best suited for 
proteins lacking  internal disulfide bonds [36].  
Thus, one needs a technique that is orthogonal to glycosylation, that can be applied even 
to non-glycosylated proteins, and that allows finer control over shielding of selected 
regions of a protein antigen.  To that end, we have developed an approach, termed as 
“Nanopatterning”, which combines site-specific incorporation of unnatural amino acids 
[45, 46] with biochemical conjugation to a shielding agent such as PEG.  
Fig. 3 shows a schematic of the nanopatterning approach. A model protein is shown in 
purple with a certain epitope of interest to be shielded shown in cyan. An immune response 
to this antigen would result in antibodies binding to the epitope of interest (cyan) and those 
that bind elsewhere on the protein (purple). To nanopattern this protein, with the goal of 
selectively shielding the cyan epitope, residues around this epitope can be identified to 
incorporate the unnatural amino acid p-azido-L-phenylalanine (F*). Next, the reactive 
azide group of F* allows the site-specific functionalization with PEG-DBCO 
(Dibenzocyclooctyne) via copper-free click cycloaddition [47]. This controlled 
conjugation of the PEG shield results in the nanopatterned mutant, which selectively 
suppresses the immune response to the epitope of interest (illustrated by elimination of 
“cyan” antibodies from the resulting response). Tuning the location of incorporation of F* 





Figure 3. Schematic for the Nanopatterning approach. A model protein shown in 
purple (top left) with a certain epitope of interest (in cyan) to be shielded. The immune 
response from this antigen would result in antibodies binding to both the epitope (cyan) 
and to other regions (purple). Residues in yellow show are sites identified around the 
epitope of interest, to incorporate the unnatural amino acid F* expressing the reactive 
azide moiety. On conjugating to PEG-DBCO, the epitope of interest is selectively 
shielded, resulting in selective suppression of the immune response. 
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2.2 Materials and Methods 
2.2.1 DNA design and Protein Expression and Purification 
DNA encoding superfolder green fluorescent protein (PDB ID: 2B3P), SpyCatcher (PDB 
ID: 4MLI) [48], PfMSP119 (Wellcome allele, PDB ID: 1CEJ) [49] and PyMSP119 (P. yoelii 
yoelii, isolate 17 xnl, PDB ID: 2MGP) [50] was optimized for expression in E. coli and 
synthesized by Integrated DNA Technologies, Inc. with C-terminal hexahistidine tags. 
SpyCatcher had an additional N-terminal Streptag® II. GFP had an additional N-terminal 
SpyTag [48]. The genes were then cloned in a modified pET28b vector using Gibson 
cloning (E5520S, New England Biolabs, Ipswich, MA) using primers designed using the 
NEBuilder tool and following manufacturer’s instructions. A version of PyMSP119 with a 
StreptagII replacing the hexahistidine tag was designed by Site-directed mutagenesis 
(SDM), performed using the Q5-SDM kit (E0554S, New England Biolabs) following 
manufacturer’s instructions. Primers for SDM were designed using the NEBase changer 
tool. DNA for GFP Nanobody (NB) (PDB: 3OGO) and PyMSP119 (P. yoelii nigeriensis, 
isolate N67) [51] was optimized for expression in E. coli and synthesized and cloned in a 
modified pET28b vector between NdeI/XhoI sites by Gene Universal Inc., Newark, DE. 
GFP NB had a C-terminal c-myc tag followed by a hexahistidine tag for purification and 
PyMSP119 (N67 isolate) had a C-terminal Strep-tag® II for purification. 
For protein expression, the plasmids encoding GFP, SpyCatcher, and NB were transformed 
into BL21 (DE3) chemically competent E. coli cells (C2527H, New England Biolabs) and 
all plasmids for MSP119 were transformed into Origami™ 2(DE3) competent E. coli cells 
(71408-3, MilliporeSigma) and grown at 37°C in 2xYT media with 35 µg/mL of 
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kanamycin overnight. The starter cultures were scaled up to the appropriate culture volume 
and grown at 37°C. Expression was induced with 1 mM Isopropyl-beta-D-thiogalactoside 
(IPTG) at OD ~ 0.8-0.9. After induction the temperature was lowered to 16°C and 
expression continued overnight. For the expression of proteins containing the non-
canonical amino acid (ncAA) p-azidophenyl alanine (F*), cells were co-transformed with 
pEvol-pAcFRS.2.t1 (Addgene plasmid # 73544) to add the machinery to allow 
incorporation of the unnatural amino acid at the amber codon (TAG). Cell cultures in this 
case were additionally supplemented with 35 µg/mL of chloramphenicol. At the time of 
induction at OD ~ 0.8-0.9, 1 mM IPTG 0.02% L-arabinose and 1 mM F* (06162, Chem-
Impex International Inc.) were added and expression continued overnight at 16°C.  
After expression, for hexahistidine tagged proteins, the cells were pelleted at 6,000-
8,000xg for 15 min and gently resuspended in binding buffer buffer [20 mM Tris, 500 mM 
NaCl, 20 mM imidazole, 5% (v/v) glycerol, pH 8.0] supplemented with a protease inhibitor 
tablet (S8830, Sigma-Aldrich), lysozyme (0.5 mg/mL; J60701, Alfa Aesar), and benzonase 
(0.5 μL; E1014, Sigma-Aldrich). The cells were then incubated on ice for 10-15 min with 
intermittent mixing. Sodium deoxycholate (302-95-4, Alfa Aesar) was added to achieve a 
final concentration of 0.1% (w/v) before sonication for a total of 6 min (3 s on, 3 s off and 
25% amplitude; Sonifier S-450, Branson Ultrasonics). The cell debris was then sedimented 
at 25,000xg (30 min). The supernatant was filtered (0.45 μm filter; 6869-2504, GE 
Healthcare) before purification of the hexahistidine-tagged proteins via Immobilized Metal 
Affinity Chromatography (IMAC) at 4 °C. The supernatant was passed twice over a bed of 
2 mL Ni-NTA resin (88222, Thermo Fisher Scientific) in a drip column (786-197, G-
Biosciences) that was pre-equilibrated in the binding buffer (20 mM Tris, 500 mM NaCl, 
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20 mM imidazole, 5% v/v glycerol, pH 8.0). The resin was then washed with 25 column 
volumes of the binding buffer. For elution, one column volume of elution buffer (20 mM 
Tris, 500 mM NaCl, 400 mM imidazole, 5% v/v glycerol, pH 8.0) was incubated with the 
resin for 4-5 min. This elution step was repeated four additional times to obtain five column 
volumes of the eluted protein. Finally, the protein was concentrated to 1 mL using spin 
concentrators (Amicon Ultra-15, 10 kDa MWCO, Millipore Sigma) and further purified 
via size-exclusion chromatography using a Superdex 75 10/300 GL column (GE 
Healthcare) on an AKTA Pure purification system (29018224, GE Healthcare) with a PBS 
running buffer (0.5 mL/min). 
For purification of proteins with a Strep-tag® II, StrepTrap chromatography was 
performed. Cells were harvested as described above except the binding buffer used was 
(100 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 8.0). After harvesting, the clarified lysate 
was run through a 5 mL StrepTrap HP column (28-9075-47, GE Healthcare) on an AKTA 
start purification system (29022094, GE Healthcare) at a flow rate of 0.5 mL/min. The 
column was next washed with the binding buffer (8-10 column volumes) followed by 
elution with 2-3 column volumes of the elution buffer (100 mM Tris, 150 mM NaCl, 1 mM 
EDTA, pH 8.0, 2.5 mM desthiobiotin).   All proteins were finally purified using size 
exclusion chromatography (SEC) on a Superdex 75 Increase 10/300 GL column (GE 
Healthcare, 29-1487-21) in PBS buffer. The SEC refining step removes aggregates if any. 
The proteins were concentrated and stored at 4°C in the dark until further use. 
The DNA for light and heavy chain variable regions (VL and VH resp.) for Fab 12.10 
(sequence obtained from [52]) were optimized for mammalian expression and synthesized 
and cloned in TGEX-LC and TGEX-FH vectors respectively by Gene Universal Inc. 
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(Newark, DE). A hexa-histidine tag was incorporated at the C-terminus of the heavy Fab 
chain for purification purposes. Further, a version of PfMSP119 fused to Fab12.10 was also 
designed. The DNA for PfMSP119 was optimized for mammalian expression, synthesized 
and cloned upstream of the LC for Fab12.10 in TGEX vector spaced by 3x repeats of 
flexible GGGGS linker, by Gene Universal Inc. (Newark, DE). Fab12.10 and PfMSP119-
3xG4S-12.10Fab were expressed in HEK293F suspension cells using the ExpiFectamine™ 
293 transfection kit (A14524, Gibco) using manufacturer’s protocol. After expression, the 
cell culture supernatants were thoroughly dialyzed against PBS and Fabs were purified by 
IMAC followed by SEC on a Superdex 75 Increase 10/300 GL column (GE Healthcare, 
29-1487-21) in PBS buffer. The SEC refining step removes aggregates if any. The purified 
proteins were concentrated, quantified using the Bicinchoninic acid (BCA) assay, and 
stored at 4°C until further use. 
2.2.2 PEGylation and Purification 
The unnatural amino acid F* was incorporated into GFP at residues 175 (S175F*) and 204 
(Q204F*) for Mut1-NB* and at residues 111 (E111F*) and 190 (D190F*) for Mut2*. 
Similarly, F* was incorporated into PfMSP119 at residues 11 (Q11F*) and 84 (Y84F*) for 
PfMutI*; 36 (Q36F*) and 58 (A58F*) for PfMutB1*; 40 (K40F*) and 71 (G71F*) for 
PfMutB2*; 36 (Q36F*), 58 (A58F*), 40 (K40F*) and 71 (G71F*) for PfMutB* (quadruple 
mutant); 13 (N13F*) and 87 (N87F*) for PyMutI*; and 38 (K38F*), 43 (T43F*), 61 
(P61F*), and 74 (S74F*) for PyMutB* (quadruple mutant).  The purified mutants 
incorporating the non-canonical amino acids were then allowed to react with 4-5 fold 
stoichiometric excess (per F*) of mPEG-DBCO (2k, 5k or 10kDa, Nanocs Inc., Boston, 
MA). The reaction mixture was left at 4°C in the dark overnight and then run on SDS-
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PAGE to determine the extent of PEGylation. The completely PEGylated mutant proteins 
(doubly or quadruply PEGylated) were purified by SEC using a HiLoad 16/600 Superdex 
200 column (GE Healthcare) on an AKTA Pure purification system (GE Healthcare) in 
PBS. The purified PEGylated proteins were concentrated and quantified using a BCA assay 
(#23227, Thermo Scientific) and stored at 4°C until further use. 
2.2.3 Multivalent display of antigen on a tetrameric scaffold 
All GFP antigens were expressed with an N-terminal SpyTag. A SpyCatcher mutant with 
F* incorporated at residue56 (T56F*) was expressed in BL21 (DE3) E. coli cells and 
purified by IMAC followed by StrepTrap chromatography and then allowed to react with 
a 4-arm branched polyethylene glycol scaffold (5 kDa PEG arms with terminal DBCO 
groups) (Creative PEGworks, Chapel Hill, NC). The protein was added at a 4-fold 
stoichiometric excess (per DBCO group) and the reaction was allowed to proceed at 4°C 
in the dark overnight. The reaction mixture was characterized by SDS-PAGE to confirm 
the formation of tetrameric product, which was separated from the incompletely reacted 
products by SEC using a HiLoad 16/600 Superdex 200 column (GE Healthcare) on an 
AKTA Pure purification system (GE Healthcare) in PBS. The tetrameric scaffold was 
concentrated and quantified using the BCA protein assay.  
The GFP antigens with an N-terminal SpyTag were then allowed to react with the 
tetrameric SpyCatcher scaffold overnight at 4°C. The SpyTag-SpyCatcher pair 
spontaneously forms an isopeptide bond [48], thereby immobilizing the antigens on the 
tetrameric scaffold, and enabling its multivalent display. The final tetrameric-GFP mutants 
were purified using SEC and characterized by SDS-PAGE. The amount of GFP in the final 
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tetrameric form was quantified using a fluorescence-based assay (λex=400 nm; λem=509 
nm). 
2.2.4 Characterization by ELISA and analytical SEC 
Anti-PfMSP119 antibodies 12.8, 12.10, 7.5 and 2.2 were procured from The European 
Malaria Reagent Repository (University of Edinburgh, Scotland). Anti-His antibody 
(MA1-21315, Invitrogen), anti-GFP antibody GF28R (MA5-15256, Invitrogen), and anti-
c-myc-HRP antibody (A00173, Genscript) were commercially procured. The 
nanopatterned antigens were characterized by ELISA to confirm the ability to block 
recognition to desired regions. Briefly, 50 µL of 0.002 mg/mL of the antigen solution was 
coated per well on ELISA plates (Maxisorp NUNC, Thermo Scientific) overnight at 4°C 
in PBS. Plates were blocked with 100 µL of 5% Bovine serum albumin (BSA) (12659, 
EMD Millipore) in PBST (PBS with 0.05% Tween-20) for 1 hr at RT. After 3x washes 
with PBST, plates were incubated with 50 µL of primary antibody solutions in 1% BSA in 
PBST for 1 hr at RT. After 3x washes with PBST, plates were incubated with an appropriate 
HRP-conjugated secondary antibody for 1 hr at RT. After 3x washes with PBST, plates 
were developed with TMB substrate solution (00-2023, Thermo Fisher) for 5 min and 
stopped using 160 mM sulphuric acid solution. Plates were read on a Spectramax i3x plate 
reader (Molecular Devices) at 450 nm. Experiments were performed in triplicates. 
Further, an SEC shift assay was performed to confirm the ability of PfMutB*-PEG to bind 
to the inhibitory Fab 12.10. All SEC chromatograms were run on Superdex 75 Increase 
10/300 GL column (GE Healthcare, 29-1487-21) in PBS buffer using 3µg of antigen (on a 
PfMSP119 basis). A stoichiometric amount of the Fab12.10 was mixed with PfMutB*-PEG 
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and then run on the SEC. Individual runs for Fab12.10 and PfMutB*-PEG were separately 
performed. Chromatograms were recorded using UV280 and overlaid for comparison. 
2.2.5 Immunizations in mice and rabbits 
BALB/c mice were immunized with the nanopatterned GFP mutants or controls adjuvanted 
with AddaVax (InVivoGen, CA) by ProSci, Inc. (Poway, CA). Samples included 
tetrameric scaffolds presenting: (i) wtGFP; (ii) Mut1-NB*; (iii) Mut1-NB*-PEG; (iv) 
Mut2*; (v) Mut2*-PEG as well as (vi) tetrameric scaffolds alone as a control. Five mice 
were immunized per group. The protein antigens were diluted to 40 µg/mL in PBS (on a 
GFP basis). Each mouse (groups i-v) was injected subcutaneously with 2 µg of GFP.  Mice 
in the control group (vi) received an equivalent amount of scaffold as mice in the other 
groups. Mice were injected with antigen on days 0, 21, and 42. On day 70, the mice were 
terminally bled and serum was stored at -20°C until further analysis. This mouse study was 
performed under ACUP 2 as approved by the ProSci, Inc. IACUC. The study was 
performed at ProSci Inc.‘s USDA licensed, registered, and NIH/OLAW assured animal 
facility. 
Groups of five female CB6F1/J (H-2d/b) mice, 6 to 8 weeks of age, were purchased from 
The Jackson Laboratory. The animals were immunized subcutaneously on days 0, 20, 40 
and 88, in the base of the tail and the interscapular area. 7.5 µg of antigens (PyMutI*-PEG, 
PyMutB*-PEG, PBS control) were emulsified in the adjuvant Montanide ISA 51 VG 
(Seppic, Fairfield, NJ) prior to injection. All animal protocols were approved by the Emory 
University’s Institutional animal Care and Use Committee and followed accordingly. 
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The engineered nanopatterned PfMSP119 mutants were immunized in specific pathogen 
free rabbits by Covance Research Products, Inc. (Denver, PA). Samples included were: (i) 
wt PfMSP119, (ii) PfMutI*-PEG, and (iii) PfMutB*-PEG. Three rabbits were immunized 
per group. 100 µg of antigen was injected subcutaneously (SC) adjuvanted with Freund’s 
complete adjuvant (FCA) on day 0. This prime immunization was followed by 3 boosts 
with 70 µg of antigen adjuvanted with Freund’s incomplete adjuvant (FIA) on days 21, 42, 
63. On day 77, the rabbits were terminally bled and serum was stored at -20 °C until further 
use. This rabbit study was performed under ACUP 2 as approved by the Covance, Inc. 
IACUC at Covance Inc.‘s USDA licensed, registered and NIH/OLAW assured animal 
facility. 
2.2.6 Mice serum analysis and Immunodepletions 
The terminal bleed serum was assessed for endpoint titer against wt GFP or PyMSP119 
(from isolates 17XNL and N67). A version of antigens with a Strep-tag® II were used for 
ELISAs to avoid signal from anti-His serum antibodies. Briefly, 50 µL of 0.002 mg/mL 
antigen were added per well to ELISA plates and the protein was allowed to adsorb onto 
the wells overnight at 4°C in PBS. Plates were blocked with 100 µL of 5% BSA in PBST 
for 1 hr at RT. After 3x washes with PBST, plates were incubated with 50 µL of sera diluted 
four-fold starting at 1:100 in 1% BSA in PBST for 1 hr at RT. After 3x washes with PBST, 
plates were incubated with a secondary HRP-conjugated anti-mouse antibody (115-035-
003, Jackson ImmunoResearch) for 1 hr at RT. After 3x washes with PBST, plates were 
developed with TMB substrate solution (00-2023, Thermo Fisher) for 5 min and stopped 
using 160 mM sulphuric acid solution. Plates were read on a Spectramax i3x plate reader 
(Molecular devices) at 450 nm. Titers were expressed as area under the curve (AUC) 
 20 
determined using GraphPad Prism software. Appropriate positive controls were included: 
commercially procured antibody GF28R binding to GFP and an anti-Strep-tag® II 
antibody (600-401-H22, Rockland Immunochemicals Inc.) for the detection of wtGFP and 
PyMSP119. 
Immunodepletion assays for the GFP set were carried out with the pooled terminal bleed 
serum for Mut1-NB*-PEG, Mut2*-PEG, and scaffold alone controls. Briefly, GFP 
Nanobody was first immobilized on Ni-NTA beads via the hexa-histidine tag on the 
Nanobody. The beads were thoroughly washed to remove any unbound NB. Next, GFP 
with the orthogonal Strep-tag® II purification tag was incubated with the NB-coated NTA 
beads, resulting in a complex of GFP and NB immobilized on NTA beads.  After thorough 
washing to remove any unbound GFP, the GFP-NB-NTA depletant was incubated with 
serum (at a 1:200 dilution) for 3-4 hrs at 4°C. A total of 4 rounds of depletion were 
performed for all three serum samples. All incubations, washes, and serum dilutions were 
carried out in 1% BSA solution in 20 mM Tris, 500 mM NaCl, 20 mM imidazole, 5% (v/v) 
glycerol, pH 8.0. As a control, NB-negative NTA beads were used as a depletant, and serum 
samples were similarly depleted 4 times. The depleted and undepleted sera from all 3 
groups were characterized by ELISA as described above. 
2.2.7 Rabbit serum antibody purification and analysis 
PfMSP119 specific antibodies were purified from the pooled rabbit serum for each of the 
antigen samples. wt PfMSP119 was immobilized on NHS-activated Sepharose™ 4 Fast 
flow (17-0906-01, GE Healthcare) beads using manufacturer’s instructions. Briefly, wt 
PfMSP119 protein was dialyzed in a coupling buffer (200 mM NaHCO3, 500 mM NaCl pH 
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8.3). The resin beads were washed with cold 1mM HCl followed by mixing with the protein 
solution, stirred overnight at 4°C. The unreacted groups on the beads were blocked with 
100 mM TRIS-HCl, pH 8.5 for 2-3 hrs. Next the immobilized protein beads were washed 
alternatively with 100 mM acetate buffer, 500 mM NaCl, pH 4.5 and 100 mM TRIS-HCl, 
pH 8.5, repeated 3-6 times with each buffer. The resin was then packed in drip columns 
and washed with PBS buffer. The serum solution was then loaded on the columns, followed 
by a wash with PBS, finally eluting with 100mM Citric acid, pH 3. The eluted antibodies 
were immediately neutralized using 1M TRIS-HCl pH 9.0 and dialyzed against PBS, pH 
7.4. The entire purification process was carried out at 4°C.  
The purified antibodies were characterized by ELISA to confirm binding to wtPfMSP119. 
SEC shifts were performed for the purified antibodies by complexing with PfMSP119-
3xG4S-12.10Fab. All SEC chromatograms were run on Superdex 75 Increase 10/300 GL 
column (GE Healthcare, 29-1487-21) in PBS buffer using 3ug of PfMSP119-3xG4S-
12.10Fab (on a PfMSP119 basis). Purified rabbit antibodies from each group were run with 
PfMSP119-3xG4S-12.10Fab in a 1:1 stoichiometric ratio. Chromatograms were recorded 
using UV205 and overlaid for comparison. 
2.2.8 Statistical analysis 
AUC was calculated using a sigmoidal curve fitting. A minimum of three technical repeats 
were tested for all ELISAs, and the experiments were repeated at least three times with 
similar results. One-way ANOVA with post-hoc Tukey’s multiple comparison test was 
applied when indicated in the figure legend. All statistical analysis was performed using 
GraphPad Prism 8 (GraphPad Software Inc.) 
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2.3 Results and Discussion 
2.3.1 Engineering, Expression and Purification of Nanopatterned GFP 
We have developed a bio-inspired approach for nanopatterning protein antigens that 
combines site-specific mutagenesis with bio-orthogonal coupling to a synthetic shielding 
molecule or polymer – such as PEG. Our goal was to demonstrate that site-specifically 
conjugating PEG chains on a protein can suppress immune response locally at selected 
epitopes as opposed to a global immune suppression. As a proof of principle, we first tested 
our approach using GFP as a model antigen. GFP is a stable protein that is easy to express 
and purify; its structure is known; and anti-GFP antibodies are commercially available for 
characterization. The ‘epitope to be shielded’ was chosen to be the epitope for a GFP 
Nanobody that binds to GFP with high affinity (Kd ~ 1.4 nM) [53]. 
Fig 4A (left) shows a crystal structure complex of GFP (shown in green) bound to the NB 
(shown in magenta) (PDB ID: 3OGO). A footprint of the NB binding on GFP is marked in 
pink on GFP in Fig 4A (ii) (right). We identified residues around or within this epitope of 
interest and mutated them to incorporate the non-canonical amino acid (ncAA) para-azido 
phenylalanine (F*) using the pEvol-pAcFRS.2.t1 system (Addgene #73544) [45]. Next, 
these mutant GFP proteins were reacted with PEG-DBCO, to site-specifically conjugate 
the PEG to the protein. The reaction results in a mixture of completely PEGylated and 
incompletely PEGylated protein; the former was purified by chromatographic separation 
using SEC and characterized by SDS-PAGE. The DBCO and azide groups react covalently 
via the strain promoted alkyne-azide cycloaddition without the need of copper. The copper-
free “click chemistry” is biorthogonal, highly specific, highly stable physiologically, and 
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requires mild reaction conditions suitable for biological molecules such as protein-based 
antigens [54].  
 
Figure 3. Nanopatterning GFP. (A) Left: The structure of GFP in green bound to 
the Nanobody (NB) in pink; Right: Structure of GFP in green with the footprint of 
Nanobody (NB) marked in light pink (B) Mut1-NB*, showing residues in yellow 
around the NB epitope that were mutated to F*; conjugation to PEG-DBCO generates 
nanopatterned Mut1-NB*-PEG. (C) Nanopatterned Mut2*-PEG was designed as a 




GFP mutants were screened based on their ability to retain protein expression, protein 
yield, and protein structure (determined by binding to commercial conformational anti-
GFP antibodies in ELISAs). The selection of residues was also guided by solvent 
accessibility (to ensure efficient conjugation to the PEG chain) and their conservation 
score, (determined by a ConSurf analysis) [55] to estimate the amenability of that residue 
to mutation to F*.  Fig 4B shows design scheme for the mutant of interest (referred to as 
Mut1-NB*). In yellow are marked the residues (Ser175 and Gln204) where the UAA F* 
was incorporated using amber stop codons. On reacting with PEG-DBCO and followed by 
purification, the nanopatterned version of Mut1-NB* (referred to as Mut1-NB*-PEG) was 
obtained. As a control, another mutant of GFP was designed where the PEG chains were 
conjugated on a distant face (opposite to the NB epitope). The reaction scheme for this 
control Mut2* is shown in Fig 4C.  
Multivalency has been shown to amplify immune responses by primarily clustering B-cell 
receptors resulting in robust downstream signaling [3, 56-59]. We next displayed the GFP 
antigens on a tetrameric polymer-protein based scaffold. The scaffold was designed based 
on the spontaneous covalent isopeptide bond formation of the protein peptide pair - 
Spycatcher-Spytag that was engineered from a bacterial adhesion CnaB2 [48]. We first 
synthesized a tetrameric version of SpyCatcher by conjugating a mutant version of 
SpyCatcher expressing an azide group to a 4-arm PEG star scaffold with a terminal DBCO 
group (5000 Da per arm). The azide group on SpyCatcher was inserted replacing residue 
Thr56 with the ncAA F* using the amber stop codon. The selection of this residues was 
based on it being on the face opposite to the Spytag binding region on SpyCatcher, its 
solvent accessibility, and its conservation score (determined by a ConSurf analysis [55]). 
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All GFP mutants were expressed with an N-terminal Spytag, to allow conjugation to the 
tetrameric SpyCatcher scaffold. The reaction scheme to achieve tetrameric display of GFP 
mutants is shown in Fig 5A. The multimeric-SpyCatcher (tetramer-trimer mixture) was 
purified from the incompletely reacted components in the reaction mixture using SEC. Fig. 
5B is an SDS-PAGE gel image showing the reaction mixture of Mut1*-NB and Mut1*-
NB-PEG with the multimeric scaffold and the two SEC purified antigens on the multimeric 
scaffold. 
2.3.2 Characterization of Nanopatterned GFP mutants by SDS-PAGE and ELISA 
 
Figure 5. Multivalent display of Nanopatterned GFP. (A) Scheme for synthesizing 
multivalent GFP conjugates based on SpyCatcher-functionalized branched PEG 
scaffolds (B) SDS-PAGE gel image showing the multimeric (tetramer-trimer mixture) 




The size of PEG to shield the NB epitope was selected based on the estimated root-mean-
squared (RMS) end-to-end distance. We initially screened PEG chains of MW 2k, 5k and 
10 kDa with our mutant of interest (Mut1-NB*) and tested their ability to block recognition 
of the NB without an appreciable loss of binding to an orthogonal anti-GFP antibody 
(GF28R). This test was important because we wanted to make a judicious choice of PEG 
length that was big enough to shield the region of interest but not excessively large so that 
it would shield other regions on the protein.  
The RMS lengths for a 2k, 5k and 10kDa PEG chain are approximately 3.9 nm, 6 nm and 
8.7 nm respectively [60]. Assuming that the PEG conjugated to the protein forms a roughly 
spherical cloud [61], the corresponding radii of gyration (Rg) for 2k, 5k and 10kDa PEG 
are approximately 2 nm, 3 nm and 4.5 nm respectively. The NB epitope can be assumed to 
be circle with a diameter of 2.5-3 nm. The two residues mutated to F* for PEG attachment 
(to Mut1-NB*) were selected to be on the periphery of the epitope. This site-selection 
strategy would allow sandwiching the epitope of interest with two PEG clouds shielding 
the bulk of the NB epitope. Based on this analysis, two 5kDa PEG chains - each forming a 
PEG cloud of radius ~ 1.5 nm was thought to be appropriate to shield an epitope ~ 3nm in 
diameter.  
To confirm our understanding and to analyze the effect of PEG length on the ability to 
selectively shield the NB epitope, we synthesized PEGylated versions of Mut1-NB* using 
PEG chains of length 2k, 5k and 10kDa. Fig. 6A shows cartoons of Mut1-NB* and its 
PEGylated versions using PEG chains of lengths 2k, 5k and 10kDa. Next, we probed 
binding of the NB and an orthogonal anti-GFP antibody to these mutants in an ELISA. As 
we can see in Fig 6B, the binding of the NB to Mut1-NB* is reduced to baseline irrespective 
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of the length of PEG chain tested. Similarly, the binding of the orthogonal anti-GFP 
antibody is unaffected by the length of the PEG chain tested. It is important to note that, 
although the 2 kDa PEG is successfully able to prevent binding of the NB to the epitope 
whereas the absence of PEG does not – this is not a conclusive test to say that the 2kDa 
PEG shields would completely occlude the epitope and prevent elicitation of antibodies to 
that region. In other words, the 2 kDa PEG shields may successfully shield important 
 
Figure 6. Effect of PEG length on shielding ability of GFP epitopes. (A) Mut1-
NB* and its nanopatterned versions using 2k, 5k and 10kDa PEG (B) ELISA result 
showing binding of the NB and an orthogonal anti-GFP antibody to Mut1-NB* and 
the nanopatterned mutants with increasing PEG lengths. ELISA binding expressed as 
absorbance (mean ± SD, n=3). The labelling of the bars for the right cluster follows as 
labelled on the left. (****p<0.0001, ns – not statistically significant, determined by a 
one-way ANOVA with post-hoc Tukey’s multiple comparison between groups). (C) 
SDS-PAGE gel image showing reaction mixtures of Mut1-NB* with PEG2k, 5k and 




residues involved in binding to a monoclonal antibody like the NB, but it may or may not 
shield the epitope entirely. Hence, in this case we relied on the estimates derived from the 
 
Figure 7. Characterization of Nanopatterned GFP mutants. (A) Characterization 
of wild-type (wt), mutant, and nanopatterned GFP variants by SDS-PAGE (B) 
Characterization of binding of NB (pink bars) and an orthogonal anti-GFP antibody 
(green bars) to multivalent wt, mutant, and nanopatterned GFP variants by ELISA. 
ELISA binding expressed as absorbance (mean ± SD, n=3). (****p<0.0001, 





analysis of the Rg of PEG shields and chose to proceed with 5kDa PEG chains for our study 
– as this choice seemed closest to offering an extent of shielding corresponding to the area 
required to be blocked on GFP. 
Fig 7A shows an SDS-PAGE gel image of wtGFP, Mut1-NB*, Mut1-NB*-PEG, Mut2* 
and Mut2*-PEG (in that order from left to right). The mutants incorporating F* run similar 
to wtGFP – as expected. The mutants alone run alongside the wtGFP as expected. 
However, the doubly PEGylated mutants - Mut1-NB*-PEG and Mut2*-PEG run higher 
because of the additional mass from the two 5kDa PEG chains. All SpyTagged GFP 
variants were then reacted with the tetrameric-Spycatcher based scaffold and purified using 
SEC to remove any unreacted excess GFP. The amount of GFP in the final purified samples 
was determined by fluorescence using a standard curve determined from wt GFP standards. 
We further characterized the multivalent conjugates by ELISA. Fig 7B shows the ELISA 
result showing binding of anti-GFP antibodies – the Nanobody and GF28R (which binds 
to the N-terminus of GFP) to wt GFP, the unPEGylated mutants Mut1-NB* and Mut2* and 
their nanopatterned versions. Binding of both antibodies to the unPEGylated mutants is 
comparable to that with wt GFP, suggesting that the mutations alone do not block binding. 
However, the relative binding of the NB drops for Mut1-NB*-PEG relative to the 
orthogonal anti-GFP antibody GF28R binding. Mut2*-PEG, on the other hand behaves as 
expected, and binds to both antibodies similar to wt GFP. This shows the ability to 
modulate the recognition of antigens by antibodies by site-specifically conjugating PEG 
shields to its surface. 
2.3.3 Nanopatterning refocuses the immune response of GFP 
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To understand if this nanopatterning also influenced the specificity of antibodies elicited 
in vivo, we carried an animal study in mice with the engineered GFP mutants. Fig 8A shows 
the immunization schedule for the study. Serum antibody titers were determined using the 
area under the curve (AUC) method as it better captures the differences between groups, 
compared to the end-point titer method (where the true titer may be over-estimated) [62]. 
Titer results (Fig 8B) showed that all five multivalent GFP conjugates elicited anti-GFP 
responses, but the scaffold alone control did not, as expected. Furthermore, the titers for 
the two PEGylated mutants were significantly lower than those for their corresponding 
non-PEGylated versions (***p<0.001, determined by ANOVA comparing all groups).  
Although the total anti-GFP serum antibody response to the two PEGylated mutants (Mut1-
NB*-PEG and Mut2*-PEG) was comparable (statistically not significant – determined by 
ANOVA comparing all groups), we were interested in determining whether the distribution 
of the elicited antibodies in terms of their specificity was different. Specifically, we wanted 
to determine whether nanopatterning has refocused the immune response for Mut1-NB*-
PEG away from the Nanobody epitope.  
Fig 8C show the hypothesized distribution of antibodies elicited by each of the two 
mutants. Mut1-NB*-PEG should only elicit orthogonal antibodies (shown in green) that 
bind to GFP on regions other than the NB epitope. Mut2*-PEG on the other hand should 
elicit antibodies binding to the epitope of interest (shown in pink) as well as orthogonal 
antibodies (shown in green). To test this hypothesis, we performed immunodepletions on 
the sera from immunized mice to isolate antibodies that bind only to the epitope of interest 
(pink), while removing all other orthogonal antibodies (green). We first immobilized the 
NB to Ni-NTA beads via the hexahistidine tag on the NB. After washing, the NB bound 
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beads were then incubated with GFP (fused to an orthogonal Strep-Tag® II as opposed to 
a hexahistidine tag). Using a Strep-Tag® II version of GFP ensures that it can only bind to 
 
Figure 8. Nanopatterning GFP refocuses the anti-GFP immune response. (A) 
Vaccination schedule in mice. (B) Serum antibody titers for the multivalent GFP 
antigens and scaffold alone are expressed as area under the curve (AUC). (C) Scheme 
illustrating the immunodepletion of anti-nanopatterned-GFP sera to remove 
antibodies (green) that bind to sites on GFP other than the NB epitope.  Antibodies 
that bind to the NB epitope are shown in pink. (D) Characterization of the binding of 
immunodepleted sera to wtGFP in the presence and absence of competing NB by 
ELISA. (****p<0.0001, ns – not statistically significant, determined by a one-way 




the beads by binding to the NB - and in doing so, the beads now present GFP with its NB 
epitope occluded (by the NB itself). Fig 8C (left) shows the depletion scheme for Mut1*, 
which should remove all orthogonal antibodies (green) with complete depletion. Fig 8C 
(right) shows the depletion scheme for Mut2*, which on the other hand should have 
residual antibodies (pink) post-depletion. The serum from the scaffold alone immunized 
mice was similarly depleted as a control.  
Next, the resulting depleted sera from the 3 samples (Mut1-NB*-PEG, Mut2*-PEG and 
scaffold control) was tested in ELISA against GFP both in presence (right bar within each 
group) and absence of competing NB (left bar within each group). As seen in Fig 8D, the 
depleted control sera (from mice immunized with scaffold control alone) did not show a 
significant difference in binding to GFP either in present or absence of competing NB. This 
sets the baseline for the experiment because this serum did not have any anti-GFP 
antibodies to begin with. Depleted sera from mice immunized with Mut2*-PEG did bind 
to GFP, but the binding was significantly reduced to baseline in presence of competing NB. 
This result indicates –as expected -that immunization with Mut2*-PEG elicits antibodies 
that bind to the NB epitope as hypothesized in Fig 8C. In contrast to that, Mut1-NB*-PEG 
did not bind significantly to GFP either in presence or absence of competing NB, 
essentially confirming that nanopatterning had completely refocused the immune response 





2.3.4 Engineering, expression and purification of nanopatterned PfMSP119  
We next extended the nanopatterning approach to a promising malarial vaccine candidate, 
Merozoite surface protein 1 (MSP1). Fig. 9 shows the MSP1 complex and its fate just prior 
to red blood cell invasion. MSP1 undergoes two subsequent proteolytic cleavage steps prior 
to invading an RBC. Most of its components are shed during this cleavage process, leaving 
behind a 19-kDa fragment called MSP119 on the parasite surface, that is carried into the 
invaded RBC [63]. MSP119 is the 19KDa C-terminal fragment of MSP1, shown to be 
critical to invasion of erythrocytes [63-65]. Inhibitory antibodies elicited against MSP119 
inhibit invasion by preventing the proteolytic cleavage of MSP1 [49].  
However,  a second class of antibodies elicited by MSP119, called “blocking antibodies”, 
interfere with the activity of inhibitory antibodies and constitute a major hurdle in 
developing an MSP119-based malarial vaccine [66]. To add to this hurdle, the extensive 
 
Figure 9. The assembly and processing of the MSP1 complex. Figure adapted from 




sequence variability of MSP119 results in a strain-specific immune response [67]. Fig 10A 
shows the extent of divergence between two strains of P. yoelii MSP119 (PyMSP119) – 
17XNL and N67 by highlighting the divergent residues in cyan (differing at as many as 21 
of 96 residues). As a result, immunization with MSP119 offers protection in mice from 
challenge with a homologous, but not a heterologous strain. Our goal was to test the ability 
of nanopatterning to selectively suppress the elicitation of “blocking antibodies” (in red in 
 
Figure 10. Challenges in vaccine development of MSP119. (A) Structure of 
PyMSP119 (PDB ID: 2MGP) with residues for inhibitory and blocking antibody 
epitopes marked in green and red respectively. Residues that differ between two 
strains of PyMSP119 (17XNL and heterologous strain N67) are marked in cyan. (B) 
Structure of PfMSP119 (PDB ID: 1CEJ) with residues involved in binding to 
inhibitory and blocking antibodies shown in green and red respectively. Blocking 




Fig 10B) and to refocus the response towards the broadly protective inhibitory epitopes (in 
green in Fig 10B).  
Fig 11A shows the protein sequence of PfMSP119 with the residues highlighted in green 
marking the conserved epitope for inhibitory antibody binding. These have also been 
highlighted in green on the crystal structure of the protein as shown in Fig 11B [49, 65]. 
As for the blocking antibody epitope, Uthaipibull et al. [68] carried out a single residue 
mutation analysis on PfMSP119 and probed the ability of those mutants to bind to blocking 
antibodies. They found that there were several residues spread across both faces of the 
 
Figure 11. Inhibitory and blocking antibody binding regions on PfMSP119. (A) 
Protein sequence of PfMSP119 with the residues involved in binding to inhibitory and 
blocking antibodies marked in green and red respectively. The numbering follows that 
as in the sequence in PDB ID: 1CEJ. (B) Structure of PfMSP119 (PDB ID: 1CEJ) in 
gray. The conserved epitope for the inhibitory antibody binding (12.8 and 12.10 Abs) 
is marked in green. Residues involved in binding to the blocking antibodies 7.5 and 2.2 




protein that affected binding of blocking antibodies. These residues have been highlighted 
in red in the sequence and the protein structure in Fig 11. Interestingly, the blocking 
antibody epitopes are closely located adjacent to the conserved inhibitory antibody epitope 
on its either side. It has been speculated that blocking antibodies interfere with the binding 
of inhibitory antibodies by either sterically blocking them or resulting in conformational 
changes that prevent inhibitory antibodies from binding [64]. 
PfMSP119 is a highly cysteine rich protein with 6 disulfide pairs for a ~12kDa protein. To 
ensure proper protein folding, we expressed the protein in Origami™ E. coli cells. These 
engineered bacterial cells have an oxidizing cytoplasmic environment which allows correct 
formation of disulfide bonds. Our goal was to shield both of the blocking epitopes (on 
either side of the protein) using the nanopatterning approach we developed. As a control, 
we also designed a version of the protein to shield the inhibitory epitope. Guided by the 
location of inhibitory and blocking antibody epitopes on the protein structure, we identified 
residues around each of the 3 epitopes to be shielded (1 inhibitory epitope and 2 “blocking” 
epitopes); the incorporation of the ncAA F* at these residues would allow modification 
with PEG and shielding.  
We screened various residues on either side of each epitope, and ultimately selected a pair 
of residues sandwiching the epitope of interest. This selection was guided by factors 
including: the proximity of the residues to the epitope, their solvent accessibility, and their 
conservation score. We first identified residues on either side of the epitope of interest (the 
one to be shielded), that were solvent accessible – determined from the crystal structure of 
the protein. Next, the candidate sites selected, were further narrowed down based on their 
conservation score as determined by ConSurf Analysis [55]. ConSurf generates a score for 
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every residue of the protein on a scale of 1 to 9, with 1 being most variable and 9 being 
most conserved. Residues with a score of lower than or equal to 5 are generally amenable 
to mutations, in our experience. Further, the ConSurf analysis reports what other amino 
acids a particular residue of interest is found to mutate to, based on its frequency in other 
homologous proteins. This information is helpful because one can preferentially pick sites 
that are compatible with mutations to an amino acid that is closer in structure to the non-
canonical amino acid to be incorporated. For example, when attempting to incorporate p-
azidophenylalanine (F*), one could pick sites that are compatible with mutations to a 
phenylalanine (F) or a tyrosine (Y).  
Using these guidelines we identified residues Q6, V8, Q11, Q14, and Y84 around the 
conserved inhibitory epitope, and expressed double mutants Q14Y84, V8Y84, Q6Q14 and 
Q11Y84 and nanopatterned them. Similarly we identified residues Q36, N50, and A58 
around the blocking antibody epitope 1, and expressed double mutants Q36N50 and 
Q36A58 and nanopatterned them. For the blocking antibody epitope 2, K40, E43, G71, 
K73, and T75 were identified to generate double mutants K40E43, E43G71, E43K73, 
E43T75, K40G71 and single mutant E43. An additional important factor for consideration 
was the protein yield, which can vary considerably among the different variants. 
After screening various combinations of double mutants for each of the 3 epitopes based 
on the binding of conformational anti-PfMSP119 antibodies in ELISA, we selected the best 
pair of sites for mutation and the subsequent site-selective attachment of PEG shields. This 
selection was ultimately based on the ability to best shield the epitope of interest without 
affecting binding to antibodies to other epitopes. MutI* (Q11Y84) is referred to as the 
mutant incorporating F* around the conserved inhibitory epitope. MutB1* (Q36A58) and 
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MutB2* (K40G71) were double mutants, each incorporating two F* residues around one 
of the two blocking antibody epitopes.  
2.3.5 Characterization of PfMSP119 by SDS-PAGE, ELISA and analytical SEC 
Based on our findings from the GFP system, we found that two 5kDa PEG chains on either 
side of the ‘epitope to be shielded’ were optimal to completely suppress the immune 
response to the epitope. The inhibitory antibody footprint on PfMSP119 (Fig 11B in green) 
was roughly comparable to that of the GFP NB in terms of epitope area on the antigenic 
protein. This observation is also in agreement with previous findings from literature about 
the average area of epitope-paratope contact for an antigen-antibody complex [69]. 
Similarly, residues marked in red in Fig 11B served as a guide for the location of the 
blocking antibody epitopes.  
We nanopatterned MutI* by conjugating 2kDa and 5kDa PEG attached around the 
inhibitory epitope to shield binding to inhibitory antibodies 12.8 and 12.10 (Fig 12A top 
panel). We then probed binding of the inhibitory antibodies to wtPfMSP119 (gray bars), 
MutI* (dark green), and the 2k (green) and 5k (light green) PEGylated version of MutI*. 
Fig 12A (bottom panel) shows the result for the ELISA. Interestingly, we see that the 2k 
PEG shields were insufficient at completely shielding the binding of the inhibitory 
antibodies 12.8 and 12.10, but the 5k PEG shields resulted in complete shielding with 
binding dropping down to baseline levels. An anti-His antibody was included as a 
normalization control. ELISA binding was expressed as absorbance at 450 nm (mean ± 
SD, n=3). Similarly, we determined the effect of PEG length on the shielding of blocking 
antibody 2.2 by conjugating 2k and 5k PEG to MutB1*. We again see a similar trend 
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suggesting that a 2kDa PEG partially shields the antibody, whereas a 5kDa PEG does so 
more completely and efficiently (Fig 13B). The effect of PEG length was more pronounced 
in thecase of MSP119 that for GFP, suggesting that a 5kDa PEG in would be required to 
shield the epitopes sufficiently. This result was in agreement with our initial calculations 
for the Rg of a random-coil polymer. Based on this finding, we chose to move forward with 
using a 5kDa for our nanopatterning attempts with PfMSP119. 
Fig 13 shows ELISA results showing the binding of inhibitory antibodies (12.8 and 12.10) 
and blocking antibodies (7.5 and 2.2) to the 3 nanopatterned mutants using a 5kDa PEG 
 
Figure 12. Effect of PEG length on shielding PfMSP119. (A) Top: Cartoons showing 
MutI* (shielding the conserved inhibitory epitope) PEGylated with 2k and 5kDa PEG. 
Bottom: ELISA results showing binding of inhibitory antibodies 12.10 and 12.8 to 
MutI* and the two PEGylated versions. (B) Top: Cartoons showing MutB1* (shielding 
the blocking epitope for antibody 2.2) PEGylated with 2k and 5kDa PEG. Bottom: 
ELISA results showing binding of blocking antibody 2.2 to MutB1* and the two 
PEGylated versions. ELISA binding expressed as absorbance (mean ± SD, n=3). The 
labelling of the bars follows as labelled for the left cluster in each set. (****p<0.0001, 
ns – not statistically significant, determined by a one-way ANOVA with post-hoc 




chain to shield. Fig 13A shows the MutI* with residues highlighted in orange (Gln11 and 
Tyr84) that were mutated to pAzF to allow conjugation to mPEG5k-DBCO. After reaction 
with mPEG5k-DBCO, the protein was purified by SEC to remove unreacted PEG and 
incompletely PEGylated products, to result in MutI*-PEG that was nanopatterned to shield 
the inhibitory epitope (serving as a control mutant). The ability of MutI*-PEG to prevent 
binding of inhibitory antibodies (12.8 and 12.10) while retaining binding to blocking 
antibodies (2.2 and 7.5) was determined by ELISA. The results are shown in the right panel 
in Fig 13A. Each cluster of 3 bars corresponds to the binding of a particular antibody 
(12.10, 12.8, 7.5, 2.2 or anti-His) to wtPfMSP119, MutI* and MutI*-PEG. The clusters have 
been colored to show the inhibitory antibodies in green, blocking antibodies in red and 
anti-His in gold; with the signal for wt PfMSP119 in each case shown in gray. As expected, 
MutI*-PEG efficiently blocks the binding of both inhibitory antibodies but does not affect 
the binding of the two blocking antibodies. Further, MutI* alone does not disrupt binding 
to any of the conformational antibodies indicating that the shielding is the effect of site-
specific functionalization with PEG and not due to the mutations alone. Fig 13B and C 
similarly show the reaction and design scheme for the blocking mutants MutB1* (to shield 
blocking antibody 2.2 binding) and MutB2* (to shield blocking antibody 7.5 binding).  
Residues Gln36 and Ala58 were mutated to F* (shown in yellow) for MutB1* and residues 
Lys40 and Gly71 mutated to F* for MutB2*. For both blocking mutants, we can see that 
their nanopatterned versions selectively prevent binding of the antibody of interest, leaving 
binding to other antibodies only marginally affected.  
Having individually characterized the nanopatterning of either blocking epitope (on each 
of the two faces of the protein), we next attempted to design a quadruply PEGylated mutant 
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MutB*-PEG that collectively shields binding to both blocking antibodies on the protein. 
We expressed, purified and PEGylated the quadruple mutant MutB* with mPEG5k-DBCO 
and further purified the quadruply PEGylated mutant MutB*-PEG using SEC. We first 
 
Figure 13. Characterization of nanopatterned PfMSP119 by ELISA.  Binding of 
Inhibitory antibodies  12.8 and 12.10, and blocking antibodies 2.2 and 7.5 to MutI*-
PEG (A), MutB1*-PEG (B) and MutB2*-PEG (C) are shown for all four antibodies 
and an anti-His antibody (as a normalization control). Binding for the correponding 
unPEGylated mutants (dark green (for inhibitory antibodies ) or dark red (for 
blocking antibodies)) and wtPfMSP119 (gray bars) is also shown in each case for 
comparison. MutI*-PEG (A) selectively shields binding of inhibtory antibodies 12.8 
and 12.10 while retaining binding to the blocking antibodies. Similarly, MutB1*-PEG 
and MutB2*-PEG selectively shield binding to blocking antibodies 2.2 and 7.5 
respectively. ELISA binding expressed as absorbance (mean ± SD, n=3). (**p<0.01, 
****p<0.0001, determined by a one-way ANOVA with post-hoc Tukey’s multiple 




characterized MutB*-PEG by SDS-PAGE. Fig. 14A shows the reaction mixtures of 
PfMutI* (left gel image) and PfMutB* (center gel image) reacted with PEG5k and run on 
SDS-PAGE, showing the mutant proteins with one, two, three, or four PEG chains 
conjugated (marked by arrows). In Fig 14A (far right) we see that the increment from wt 
 
Figure 14. Characterization of Nanopatterned PfMSP119 by SDS-PAGE and 
analytical SEC. (A) SDS-PAGE images showing – Left: Single and double 
PEGylated PfMutI* Center: Single, double, triple and quadruple PEGylated PfMutB*, 
Right: wt PfMSP119, the purified double PEGylated control mutant PfMutI*-PEG, 
and the purified quadruply PEGylated mutant of interest PfMutB*-PEG (B) 
Analytical SEC shifts showing the ability of the quadruply PEGylated mutant 




PfMSP119 to PfMutI*-PEG (two 5k-PEGs added) to PfMutB*-PEG (total of  four PEG5k 
conjugated) is characteristic of the behavior of PEG conjugated to a protein run on SDS-
PAGE (PEG runs higher than its true molecular weight on SDS-PAGE [70]). 
Next, it was important to ensure that the quadruply PEGylated MutB*-PEG binds to the 
exposed inhibitory epitope (to where it is expected to refocus the immune response to). We 
first attempted ELISAs by similarly coating this nanopatterned antigen on plates to probe 
binding to the inhibitory and blocking antibodies. However, because of the presence of 
four PEG chains on a 12kDa protein it was difficult to coat the quadruple mutant effectively 
on ELISA wells. As an alternative, we performed an in-solution binding assay using 
analytical SEC to ensure that the MutB*-PEG binds to the inhibitory antibody. The results 
from this analytical SEC shift assay are shown in Fig. 15B. We expressed and purified the 
inhibitory Fab 12.10 from mammalian 293F cells. We then ran MutB*-PEG, Fab 12.10, 
and a complex of MutB*-PEG on an SEC column and the overlaid chromatograms are 
shown in Fig 14B. Fab 12.10 exhibits a peak at ~12 mL (orange chromatogram); PfMutB*-
PEG peaks at ~9.3 mL (because of an increased hydrodynamic radius from conjugating 
four PEG chains); and a complex of the same amounts of PfMutB*-PEG and Fab 12.10 
exhibits a peak at ~9.2 mL (gray chromatogram). As can be seen for the chromatogram for 
the mixture of PfMutB*-PEG and Fab 12.10, we do not see a peak for the Fab 12.10 alone 
and the intensity of the peak at ~9.2 mL is significantly higher than that of the peak for Fab 
alone – confirming that MutB*-PEG was able to bind to the inhibitory Fab 12.10.  
2.3.6 Nanopatterning refocuses the immune response to PfMSP119 
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Having shown that the nanopatterned PfMSP119 mutants were able to selectively block 
recognition of either inhibitory (PfMutI*-PEG) or blocking antibodies (PfMutB*-PEG), 
we next immunized rabbits with these antigens to determine whether this selective 
recognition of antibodies in vitro translates to an altered immune response in vivo.  
The immunization schedule is shown in Fig. 16A. The animals were terminally bled on 
day 77 and the sera were tested by ELISA to determine titers. Both antigens (PfMutI*-PEG 
and PfMutB*-PEG) showed an anti-PfMSP119 response (Fig. 15C). The quadruply 
PEGylated PfMutB*-PEG showed relatively lower titers compared to the doubly 
PEGylated PfMutI*-PEG – as expected – because of a larger area of the antigen shielded.  
Next, it was important to test if the specificity of the elicited antibodies for the two mutants 
were different. To probe this difference in specificity, we first purified anti-PfMSP119 
specific antibodies from the serum by performing antigen-specific affinity column 
chromatography.  
Next we synthesized a version of PfMSP119 fused to the inhibitory Fab 12.10 by co-
expressing the antigen and Fab spaced by 3 repeats of GGGGS – termed PfMSP119-
12.10Fab (Fig. 15B (far right)). This version of PfMSP119 shields the inhibitory epitope 
(by the presence of the tethered Fab), in effect, preventing inhibitory antibodies from 
binding to this antigen. The ability of PfMSP119-12.10Fab to block binding to inhibitory 
antibodies was confirmed by ELISA and analytical SEC. This version of PfMSP119 thus 
serves as a reagent to probe the relative presence or absence of inhibitory antibodies in an 
antibody sample.  
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We next tested the relative binding of purified rabbit serum antibodies resulting from 
immunization with either PfMutI*-PEG or PfMutB*-PEG to PfMSP119-12.10Fab and 
analysed the extent of antibody binding using analytical SEC. Fig 15D shows an overlay 
of chromatogram results from this experiment. The gray chromatogram is for the 
PfMSP119-12.10Fab fusion protein alone. This fusion protein of PfMSP119 and the 12.10 
Fab runs slightly to the left of where a typical Fab runs, as expected. Chromatograms for 
purified polyclonal antibodies elicited by immunization with PfMutI*-PEG and PfMutB*-
PEG are shown in light red and light green respectively. The amount of antibody in each 
case was stoichiometric to the PfMSP119. Interestingly, when these purified antibodies 
 
Figure 15. Nanopatterning PfMSP119 refocuses the immune response. (A) 
Immunization schedule in rabbits (B) Left and center: Nanopatterned PfMSP119 
antigens PfMutI*-PEG and PfMutB*-PEG; Right: Cartoon showing PfMSP119 tethered 
to the inhibitory Fab 12.10 (in light green). (C) Serum antibody titers against wt 
PfMSP119 from the three immunized groups (D) Overlaid SEC chromatograms for the 





were mixed with PfMSP119-12.10Fab (stoichiometrically) and run on the SEC, the extent 
of peak shifts we see in the two cases were different. The peak for purified antibodies 
elicited by immunization with PfMutI*-PEG (the control antigen that should elicit fewer 
inhibitory antibodies and more blocking antibodies) shifts much more to the left when 
mixed and run on the SEC with a stoichiometric amount of PfMSP119-12.10Fab. Further, 
the peak also increases in intensity suggesting that most of these antibodies bound to the 
PfMSP119-12.10Fab fusion protein (dark red chromatogram). In contrast to that, the peak 
for purified antibodies elicited by immunization with PfMutI*-PEG (the antigen that 
should elicit fewer blocking antibodies and more inhibitory antibodies) shift to a small 
extent with only a marginal increase in intensity (shown in dark green). Furthermore, we 
also see a peak for the PfMSP119-12.10Fab fusion protein alone, suggesting that antibodies 
elicited by PfMutI*-PEG are primarily specific to the inhibitory epitope.  Overall, this data 
suggests that there was a higher fraction of inhibitory antibodies elicited for PfMutB*-PEG 
than for PfMutI*-PEG – essentially confirming that nanopatterning refocused the immune 
response of PfMSP119 towards the conserved inhibitory epitope.  
2.3.7 Translating findings to PyMSP119 
One important application of nanopatterning protein antigens is to elicit broadly protective 
antibodies across strains. Although MSP-1 is highly divergent for P. falciparum, the 19kDa 
fragment of MSP-1 is fairly conserved [71]. The rodent parasite plasmodium species – P. 
yoelii - on the other hand, shows significantly greater variability in sequence of PyMSP119 
between parasite strains (at as many as 21 of 96 residues) than PfMSP119. Hence, we 
translated findings from the P. falciparum system to the P. yoelii MSP119 as the latter 
represented a more challenging test for our approach.  
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PfMSP119 and PyMSP119 are highly divergent in sequence, only sharing ~50% homology. 
This divergence can be seen in Fig 16A where the MSP119 sequences for PfMSP119 and 
PyMSP119 are aligned and divergent residues are highlighted in cyan. Despite being 
divergent in sequence, MSP119 from these two species shares a high degree of structural 
similarity as shown in Fig 16B with the PfMSP119 ribbon structure in yellow and that for 
PyMSP119 in magenta (generated using an academic version of PYMOL). However, the 
anti-PyMSP119 inhibitory and blocking antibody epitopes are not mapped precisely as they 
are for PfMSP119. Therefore, to guide our nanopatterning efforts, we relied on the structural 
and functional similarity of Pf and PyMSP119. We first mapped the epitopes for anti-
 
Figure 16. Translating findings from PfMSP119 to PyMSP119. (A) Alignment and 
comparison of the protein sequences for P. falciparum (Pf) and P. yoelii (Py) MSP119. 
Residues that differ between the two sequences are highlighted in cyan. (B) Structural 
alignment of Pf and Py MSP119 (C) Top Panel: Structure of PfMSP119 (PDB ID: 1CEJ), 
with residues involved in binding the inhibitory antibodies shown in green and residues 
involved in the binding of blocking antibodies shown in red. Residues mutated to F* to 
allow site-specific PEGylation to shield the inhibitory antibody epitope are colored 
orange.  Residues mutated to F* to enable shielding of the blocking antibody epitopes 
are colored yellow. Bottom Panel: Analogous regions (inhibitory epitope, blocking 





PfMSP119 antibodies onto the PyMSP119 structure using exact analogs based on sequence 
alignment. Fig 16C shows in the top panel the structure of PfMSP119 (front and back faces) 
with the epitope for inhibitory antibody binding shown in green and residues involved in 
binding to blocking antibodies shown in red. The bottom panel shows the structure of 
PyMSP119 with the analogous inhibitory and blocking antibody epitopes mapped. Next, 
we mapped residues that were mutated to F* to shielding the inhibitory epitope on 
PfMSP119 (marked in orange) and blocking epitopes (marked in yellow) – onto the 
PyMSP119 structure.  
2.3.8 Nanopatterning refocuses the immune response of PyMSP119 
Fig. 17A (left) shows the structure of PyMSP119 (from strain 17XNL) in dark gray with 
the residues for inhibitory antibody binding and blocking antibody binding mapped in 
green and red respectively. Fig. 17A (right) shows the structure of PyMSP119 with residues 
in cyan highlighting the differing residues between highly divergent strains 17XNL and 
N67. We expressed and purified PyMSP119 from strain 17XNL and further generated two 
mutants: the double PEGylated mutant PyMutI*-PEG serving as a control and the 
quadruply PEGylated mutant PyMutB*-PEG, shielding the two “blocking epitopes” – to 
refocus the immune response to the conserved inhibitory epitope. 
We immunized mice with these antigens and analysed anti-PyMSP119 serum antibody titers 
by ELISA against both homologous (17XNL strain) and heterologous (N67 strain) 
PyMSP119. Both antigens were expressed and purified with a Strep-tag® II (as opposed to 
a hexa-histidine tag for the antigens used for immunizations) to prevent any false positive 
signal resulting from anti-His serum antibodies. Fig 17D shows the serum antibody titer 
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data expressed as area under the curve (AUC) for both mutants – MutI*-PEG and MutB*-
PEG against homologous and heterologous PyMSP119. The total serum antibody response 
against homologous PyMSP119 was comparable for mice immunized with MutI*-PEG and 
MutB*-PEG (Fig. 17D). Importantly, antibodies elicited by immunization with the 
nanopatterned MutB*-PEG recognized heterologous PyMSP119 from strain N67, whereas 
those elicited using the control MutI*-PEG failed to do so. This result confirms the ability 
of nanopatterning to refocus the response of PyMSP119. This result is in agreement with 
 
Figure 17. Refocusing the immune response of PyMSP119. (A) Structure of 
PyMSP119 (PDB ID: 2MGP) with residues homologous to the PfMSP119 inhibitory and 
blocking antibody epitopes marked in green and red respectively. Right Panel: Residues 
that differ between two strains of PyMSP119 (17XNL and heterologous strain N67) are 
marked in cyan. (B) Nanopatterned mutants, MutI*-PEG (shielding inhibitory epitope) 
and MutB*-PEG (shielding blocking epitope). (C) Vaccination schedule in mice. (D) 
Anti-MSP119 antibody response for the two immunized mutants is comparable against 
homologous PyMSP119 but significantly different against heterologous PyMSP119. 




the analytical SEC results for PfMSP119 - suggesting that the immune response was focused 
in both cases (Pf and PyMSP119) towards the conserved inhibitory epitope. 
2.4 Conclusion and Future Directions 
We have developed a tool that uses site-specific conjugation of PEG chains to defined 
regions of a protein antigen, allowing modulation of protein immunogenicity on the 
nanoscale. A judicious selection of PEG length allows shielding the region of interest, 
while maintaining recognition to other regions. We have first shown the ability to 
selectively suppress the immune response to a defined epitope on GFP involved in binding 
to a Nanobody. We further applied this approach to an important malarial antigen MSP119 
that has been shown to be essential to invasion of erythrocytes. Vaccine development of 
MSP119 suffers from the elicitation of certain “undesirable” blocking antibodies that 
interfere the protective activity of inhibitory antibody. We nanopatterned MSP119 from two 
malarial species - Plasmodium falciparum and Plasmodium yoelii – and have shown that 
the nanopatterned MSP119 was successful at refocusing the immune response to the 
conserved inhibitory epitope.  
One concern with our proposed approach is the presence of pre-existing or treatment 
induced anti-PEG antibodies that may interfere with the vaccine efficacy [72, 73]. To avoid 
complications related to anti-PEG antibodies, the existing approach can be easily extended 
to other polymers replacing PEG as shields e.g., poly[oligo(ethylene glycol) methyl ether 
methacrylate] (POEGMA) [74]. 
Aside from the applications of nanopatterning in immunofocusing, the ability to tune 
antibody recognition itself is valuable. For example, this strategy can be used as a 
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diagnostic tool by engineering antigens and using them to screen the presence or absence 
of antibodies in a serum sample that bind or do not bind to regions of interest.  In addition, 
our group has already started extending the nanopatterning approach to another malarial 
antigen called P. falciparum circumsporozoite protein (PfCSP) – with the goal of 
suppressing the response to immunodominant regions and refocusing the response to other 
regions on the antigen that are naturally immunosubdominant yet protective in nature.  
While the current work involved the incorporation of a single unnatural amino acid, one 
can incorporate multiple different unnatural amino acids to conjugate to differently sized 
PEG chains on different regions of the protein antigen – allowing even finer control over 
epitope exposure [45]. Our approach can also be extended to antigens expressed in other 
expression systems such as mammalian cells [75]. 
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CHAPTER 3. DIRECTING THE IMMUNE RESPONSE TO 
CONSERVED EPITOPES ON INFLUENZA 
HEMAGGLUTININ USING TETHERED- AND 
SOLUBLE BI-FAB SHIELDS 
3.1 Introduction 
Influenza is a serious global health problem. The “Spanish” influenza pandemic of 1918 
has been estimated to have caused approximately 40 million deaths [22]. Seasonal 
influenza epidemics cause an estimated 250,000 to 500,000 deaths annually worldwide 
[21]. There are two main types of influenza viruses – type A and type B - of which type A 
is a more virulent human pathogen [76]. Influenza A viruses are further subtyped according 
to the antigenic properties of their glycoproteins – Hemagglutinin (HA) and Neuraminidase 
(NA) (Fig. 18A) [76]. The antigenic properties of HA also allow the classification of 
influenza A viruses into two major groups – group 1 and group 2 [76].  
Although commercially available influenza virus vaccines remain the most effective way 
to prevent influenza virus infection, this approach induces an immune response that is 
narrow and strain specific and it primarily targets the globular head domain of HA (Fig. 18 
B) [77, 78]. This head domain, however, is subject to rapid “antigenic drift”, enabling 
influenza viruses to escape from vaccine-induced immunity. As a result, annual 
revaccination is required with reformulated vaccines – making the process costly and time 
consuming [79]. Thus, there have been efforts in recent times to design “Universal 
Influenza vaccines” that provide protection against a broad range of strains and subtypes.  
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The antigenic structure of the A/PR/8/34 HA has been previously mapped [80, 81].  There 
are four immunodominant antigenic sites in the globular head domain, called Sa, Sb, Ca 
(composed of subsites Ca1 and Ca2), and Cb.   Sa, Sb, and Cb are each contained within a 
single monomer unit of the trimer, with Sa and Sb being close to each other near the tip of 
the globular head, whereas Cb lies near the bottom of the globular head.  Antigenic site Ca 
spans a cleft between two adjacent monomers. 
Despite the elicitation of highly potent neutralizing antibodies directed towards the head 
domain of HA, extensive amino acid substitutions in this region allow the virus to escape 
antibody-based immunity. In contrast to the highly variable head domain of HA, the 
membrane proximal stalk domain is highly conserved because it plays a role in viral 
membrane fusion to the host cell during infection [79]. Antibodies elicited against this 
 
Figure 18. Influenza virus and Hemagglutinin (A) Cartoon showing an influenza 
virus with its predominant surface proteins Hemagglutinin (HA) and Neuraminidase 
(NA) shown as spikes. (B) Structure of HA (PDB ID: 1RU7) showing the globular 
head domain and the stalk domain. The variable antigenic epitopes in the head 
domain are shown in red. The epitope for a broadly conserved stalk antibody CR6261 
is shown in blue. 
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conserved stalk domain have been shown to provide broad neutralization activity across 
influenza virus strains and subtypes [82, 83]. However, these antibodies are rare and not 
effectively induced by seasonal influenza virus vaccines. As a result, there has been a lot 
of interest in redirecting the immune response of HA towards the stem region. Several 
groups have worked in this direction by engineering HA to elicit an immune response to 
the stalk region, as discussed below. 
Krammer et al. [84] designed chimeric HA (cHA) structures combining an H1 stalk domain 
with “exotic” globular head domains derived from other influenza A virus subtypes (Fig. 
19A). They next immunized mice sequentially with these chimeric constructs, effectively 
repeatedly exposing mice to constructs that express the same stalk domain. This approach 
resulted in the robust elicitation of broadly neutralizing, stalk-specific antibodies. These 
polyclonal anti-stalk responses were shown to be neutralizing in vitro and protected mice 
against heterologous and heterosubtypic challenge [84]. However, this approach of 
immunizing sequentially with chimeric HAs has the disadvantage of eliciting some 
response to the head domain of HA – by not completely suppressing the anti-head response. 
Eggink et al. [35] used a different approach to guide the immune response to the stalk 
region of HA away from the variable head domain (Fig. 19B). They designed a 
hyperglycosylated version of HA by introducing seven N-linked glycosylation sites in the 
head domain to shield the immunodominant antigenic sites. The hyperglycosylated HA 
was found to enhance the stalk-directed response while dampening the head response on 
immunization in mice. This enhanced stalk response for the hyperglycosylated HA further 
translated to better protection upon influenza virus challenge when compared to 
immunization with wild-type HA [35].  
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The approach of hyperglycosylating HA requires inserting multiple mutations on the 
antigen that may interfere with the folding and structural integrity of the protein. 
 
Figure 19. Existing pproaches to direct the immune response of HA to the stalk 
region. (A) Strategy of sequential immunization with chimeric HAs (B) Hyper-
glycosylated HA with additional glycans in the head domain (C) A protomer of full-
length HA and its truncated stalk-only “mini-HA” version. Figure adapted from 





Glycosylation is a relatively blunt tool allowing limited ability to vary the structure of the 
glycan shields. Also, one requires protein expression systems that ensure incorporation of 
high, complex and dense glycans to achieve sufficient masking – which at the same time 
may increase the glycan density on other regions of the protein (stalk, in case of HA), and 
is incompatible with expression of recombinant proteins in hosts such as insect cells. 
Impagliazzo et al. [85] and Mallajosyula et al. [86] used rational protein engineering to 
design stalk-only HA antigens by removing the head domain altogether - referred to as 
“mini-HAs” or “headless HAs” (Fig. 19C). These stalk-only constructs exhibited binding 
to broadly neutralizing anti-stalk antibodies similar to that for full-length HA. Further, 
these immunogens completely protected mice in a lethal heterologous and heterosubtypic 
challenge model [85, 86]. There have been similar attempts in the past to engineer a stalk-
only HA, however, previous attempts exhibited lower affinity of broadly neutralizing stalk 
antibodies relative to full-length HA, indicating suboptimal conformation [87-89]. 
Recently, Deng et al. [90] immobilized headless HAs on a core of protein nanoparticles 
(composed of the influenza matrix protein 2 ectodomain) and observed long-lasting 
immunity, protecting mice against challenges with divergent influenza A viruses.  
Although, the “stalk-only” approach involving truncating the antigen down to only the 
regions of immunological interest is highly appealing and most promising among other 
approaches for a “Universal influenza vaccine”, a strategy like this involves extensive 
engineering of the antigen. To extend this tool to antigens from other infectious diseases 
would be a challenging and an involved task – requiring a unique strategy for each new 
antigen. Further, depending on the structure of the antigen and the location of the epitope 
of interest on this antigen, a truncation strategy may not always be possible.  
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The current work explores an alternative approach to precisely shield regions of a protein 
antigen from the immune system, in order to refocus the response to the broadly 
neutralizing regions. This approach involves the use of antibody fragments (Fabs), which 
are highly specific in their binding to defined regions of an antigen. We have demonstrated 
the applicability of Fabs as shielding agents to engineer Hemagglutinin by shielding its 
immunodominant, yet highly variable head domain.  
Prior exposure to Influenza antigens has been shown to influence the subsequent response 
to influenza vaccinations [62, 91-95]. This phenomenon is referred to as Original Antigenic 
Sin – in which sequential infection with viral variants produces antibodies against older 
viral strains at the expense of responses to novel or mutated antigenic variants [95]. The 
schematic in Fig 20A [1] explains this concept better. The left panel in the figure represents 
a primary infection with a virus with responses to its four epitopes shown in various colors. 
The right panel shows the case where the same patient is exposed to a mutated version of 
the virus, later in life. This drifted virus contains two novel epitopes that have mutated from 
the original version. As can be seen in the corresponding figure, the immune response to 
the shared epitopes (between the older and drifted strains) are amplified at the expense of 
the novel epitopes.  
A more recent concept that has attracted attention is Original Antigenic Suppression [62], 
in which antibodies to the shared priming epitopes, if present at high titers, can result in 
immune suppression to this shared epitope. In an interesting experiment, Angeletti et al. 
[62] vaccinated mice with an inactivated A/PR/8/34 influenza virus mixed with a Fab 
fragment specific to the Sb antigenic site of the HA head, and observed a selective 
suppression of the Sb-specific antibody response. Fig. 20B shows a cartoon with the Sb 
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Fab (purple) bound to HA, sterically blocking access to the tip of the HA head. The strength 
of Original Antigenic Suppression may be governed by the balance of Abs versus their 
cognate memory B cells. With high levels of antibody, immune response is suppressed 
(Original Antigenic Suppression); whereas, with low antibody levels, memory B cells 
dominate naïve B cells (Original Antigenic Sin), resulting in an enhanced response to the 
shared antigenic epitope.   
 
Figure 20. Original antigenic sin and Original antigenic suppression. (A) 
Schematic illustrating original antigenic sin. (B) Illustration of original antigenic 
suppression. Figure shows a Fab (in purple) complexed to HA, which on immunizing 
resulted in selective suppression of the immune response to the cognate antigenic site. 
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While this prior work was aimed at a fundamental understanding of immune responses to 
pathogens, we reasoned that an Ab or an Ab-like molecule might be used to sterically 
suppress the antibody response to any desired site.   Along these lines, we have developed 
two approaches to utilizing Fabs as shields to suppress the immune response to the head 
domain of HA. Fabs are highly advantageous as shielding agents because they bind with 
high specificity to their epitope, effectively shielding it. Moreover, Fabs are considered to 
be “self-molecules”, making them ideal as shields in the context of a vaccine. The most 
immunogenic region of a Fab is the paratope around its complementary-determining-
region (the antigen binding face) [96]. However, when presented to the immune system 
when bound to its antigen partner, this immunogenic region of the Fab would be occluded, 
thereby reducing the immunogenicity concerns related to Fabs. Despite all the advantages 
of Fabs as shielding agents, their binding to the antigen is non-covalent. And so, our 
approach involves engineering Fab-based shields with enhanced binding to the antigen. 
We have developed two approaches in this direction: tethered-Fab shields and soluble-Fab 
shields that are discussed below. 
3.2 Shielding the Hemagglutinin head using tethered-Fab shields 
Fig. 21 shows a schematic of the proposed tethering approach to shield the head domain of 
HA. Fig. 21B (top) shows a ligand receptor pair, analogous to a Fab (ligand) with its 
antigen (receptor) partner. Analysis of the thermodynamics of ligand-receptor binding 
indicates that tethering a ligand to its receptor increases the effective concentration (Ceff) 
of the ligand by constraining the ligand to the vicinity of the receptor [60, 97-99]. Fig. 21A 
(top) shows the binding of a monomeric Fab (shown in shades of purple) to the tip of the 
HA head. This case is similar to the experiment performed by Angeletti et al.[62], where 
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on immunizing mice with this complex of an Sb site binding Fab with HA the resulting 
sera showed selective suppression of an immune response to the Sb antigenic site on HA 
[62]. However, there was still a response to the head domain of HA as the other antigenic 
sites were left exposed, as shown by the incompletely shielded red epitopes in Fig. 21A 
(top).  
To build on this model, we proposed to tether the Fab (shown in purple) to HA at a site 
lower down on the head domain. The “tether” is shown in Fig. 21A (bottom) as a complex 
of the Fab with another protein (in cyan). On binding to HA, the tether and the Fab 
collectively should shield the head more completely, as seen in the Fab-tethered HA 
cartoon in Fig. 21A. In addition, tethering the Fab should also increase the affinity of the 
 
Figure 21. Schematic for tethering a Fab to Hemagglutinin to shield the head 
domain. (A) Top: HA bound to a Fab (purple) that binds to the tip of the head region; 
Bottom: Fab tethered to HA via Streptavidin (cyan). (B) Top: Cartoon showing a ligand 




Fab for HA. The stalk region is still accessible in this engineered “head-shielded” HA, 
which would allow the immune response to be refocused to the conserved stalk epitopes. 
3.2.1 Materials and Methods 
3.2.1.1 Hemagglutinin engineering, expression and purification 
Influenza Hemagglutinin (HA: strain A/Puerto Rico/8/1934 H1N1) was expressed and 
purified as previously described [100]. The DNA encoding hemagglutinin (PDB ID: 
1RU7) was optimized for insect cell expression and synthesized and cloned into 
pFastBacDual vector by GeneUniversal Inc. (Newark, DE),  under the p10 promoter. A C-
terminal trimerization domain from T4 phage fibritin followed by a hexa-histidine tag were 
also included. The DNA encoding the enzyme biotin ligase BirA, which enzymatically 
adds a biotin to the AviTag (GLNDIFEAQKIEWHE), was also insect optimized, 
synthesized and cloned under the polyhedrin promoter to allow for in vivo biotinylation of 
HA. Mutants of HA were designed with an AviTag incorporated in the head domain or the 
stalk domain to allow tethering of the Fab ligand. For the head mutant, the tag was inserted 
between residues 77 and 78 using site directed mutagenesis. This version of HA is referred 
to as hb-HA (for head biotinylated HA). For the stalk mutant, the tag was inserted at the 
C-terminus of the protein before the trimerization domain. This version of HA is referred 
to as sb-HA (for stalk biotinylated HA). 
DNA encoding a chimeric HA – cH5/1 [84] with the head domain from H5N1 and stalk 
domain from H1N1 was optimized for insect cell expression and synthesized and cloned 
into pFastBacDual vector by GeneUniversal Inc. (Newark, DE), under the p10 promoter. 
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A C-terminal trimerization domain from GCN4 followed by a Strep-tag® II were also 
included. 
HA plasmids were transformed into DH10Bac competent cells (10361012, Gibco) as per 
manufacturer’s protocol. The DNA was isolated using PureLink™ HiPure Plasmid 
Miniprep Kit (K210002, Invitrogen) and transfected in Sf9 insect cells. Baculoviruses were 
generated to a P3 stock and viral titers were measured using the BacPAK™ Baculovirus 
Titer kit (631406, Clontech). Protein expression was carried out in HiFive insect cells and 
the HA protein was purified by IMAC. HA was further purified to complete purity by 
removing larger aggregates using SEC on Superdex 200 Increase 10/300 GL column (GE 
Healthcare, 28-9909-44) in PBS buffer. HA was characterized by SDS-PAGE and ELISA 
against a panel of head and stalk binding antibodies. Gel shift assays with Streptavidin on 
SDS-PAGE were carried out to confirm biotinylation in vivo. The purified trimer of HA 
was stored at 4°C until further use.  
3.2.1.2 Design and synthesis of tethered-Fab shields 
The DNA encoding light and heavy chain variable regions (VL and VH resp.) for Fab 
H28D14 (sequence generously provided by Dr. Jonathan Yewdell, NIH [62]) and Fab 
CR6261 (PDB ID: 3GBN) were optimized for mammalian expression and synthesized and 
cloned in TGEX-LC and TGEX-FH vectors respectively by Gene Universal Inc., Newark, 
DE. A hexa-histidine tag was incorporated at the C-terminus of the heavy Fab chain for 
purification purposes. Further, versions of the two Fabs were synthesized by incorporating 
an AviTag at the N-terminus of the VL regions spaced by 5x or 10x repeats of a GGGGS 
linker. 
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The Avi-tagged Fabs (H28D14 and CR6261) were expressed in HEK293F suspension cells 
using the ExpiFectamine™ 293 transfection kit (A14524, Gibco) using the manufacturer’s 
protocol. After expression, the cell culture supernatants were thoroughly dialyzed against 
PBS and Fabs were purified by IMAC followed by SEC on a Superdex 75 Increase 10/300 
GL column (GE Healthcare, 29-1487-21) in PBS buffer. The SEC refining step removes 
aggregates if any. Next, the Avi-tagged Fabs were biotinylated using the BirA reaction kit 
(#BirA500, Avidity LLC) using the manufacturer’s protocol. Briefly, the Avi-tagged Fabs 
were buffer exchanged into 20 mM TRIS, 20 mM NaCl, pH 8.0 using spin concentrators. 
The biotinylation reaction was set up by adding the reaction components provided with the 
kit that include ATP, biotin, magnesium and biotin ligase BirA. The reaction mixture was 
incubated at 37°C for 2 hrs and then run on SEC (Superdex 75 10/300 GL) in PBS to 
separate the biotinylated Fab from the reaction components. The extent of biotinylation 
was confirmed by gel shift assays with Streptavidin on SDS-PAGE.  
Streptavidin was expressed, purified and refolded from bacterial inclusion bodies as 
previously described [101]. Briefly, the plasmid coding for Streptavidin, which includes a 
C-terminal hexa-glutamic acid tag, was procured from Addgene (#46367) and transformed 
in BL21 (DE3) cells. Inclusion bodies were harvested and purified from cells and refolded 
by rapid dilution. Tetrameric SA was precipitated using ammonium sulfate and further 
affinity purified to complete purity using Iminobiotin agarose (20221, Thermo Scientific). 
Next, to synthesize the complex of a single Fab molecule and SA (SA-monoFab), the 
biotinylated Fab was mixed with a 6-fold stoichiometric excess of SA. While SA has four 
biotin binding sites, a maximum of two biotinylated Fabs could bind simultaneously to SA 
in our experience. Using an excess of SA limits the formation of SA-biFab complexes. To 
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separate SA-monoFab (desired product) from SA-biFab (undesired) and excess SA, the 
reaction mixture was run on SEC (HiLoad 16/600 Superdex 200 column, GE Healthcare). 
The SA-monoFab was further purified to complete purity by using anion exchange 
chromatography to remove the unbiotinylated Fab that co-elutes in SEC. A MonoQ 5/50 
GL column (GE 17-5166-01, GE Healthcare) was used with 20 mM TRIS pH 8.0 as the 
binding buffer. The protein was eluted using 20 mM TRIS, 1M NaCl, pH 8.0 using a 10%-
40% gradient elution over 10 column volumes (CVs). The resulting SA-monoFab complex 
was characterized by running gel shift assays with biotinylated HA by SDS-PAGE. The 
SA-Fab complex to shield the head was synthesized by the above procedure by fusing the 
head binding Fab H28D14 with streptavidin (referred to as SA-H28D14). Similarly to 
shield the stalk domain, we synthesized a complex of the stalk binding Fab CR6261 with 
streptavidin (referred to as SA-CR6261). 
An alternative strategy to design tethered shields was also developed based on a single 
fusion of monomeric rhizavidin with the head-binding Fab H28D14. A monomeric 
enhanced version of rhizavidin (eRA) [102] was used for this purpose. DNA encoding eRA 
was cloned upstream of the VL region of H28D14 in TGEX-LC, spaced by 5x repeats of 
GGGGS, synthesized by Gene Univeral Inc., Newark, DE. The eRA-H28D14 Fab fusion 
was expressed in HEK293F cells and purified as described above.  
3.2.1.3 Characterization of Fab-tethered-HA by analytical SEC 
Biotinylated HA (hb-HA or sb-HA) was mixed with the appropriate shield (SA-H28D14 
or SA-CR6261) in a 1:1.2 stoichiometry with the shield in excess. Analytical SEC was 
performed to confirm the binding of the tethered shield to HA and further probe the ability 
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of the Fab-tethered-HAs to shield the head or stalk domain by competing with the head and 
stalk binding Fabs. Briefly, 5µg hb-HA was run on SEC (i) alone, (ii) complexed with the 
head shield SA-H28D14, (iii) complexed with the head shield and competed with 
monomeric head binding Fab H28D14, and (iv) complexed with the head shield and the 
stalk binding Fab CR6261. The absorbance was recorded by measuring UV205. A similar 
experiment was performed for sb-HA with the corresponding stalk shielding tether (SA-
CR6261) and for the rhizavidin based head shield (eRA-H28D14). 
3.2.1.4 Immunizations in mice 
BALB/c mice were immunized with the Fab-tethered head-shielded and stalk-shielded HA 
mutants (referred to as Mut T1 and Mut T2 respectively) at the Rafi Ahmed Lab (Emory 
University, GA). Samples included were: (i) hb-HA+SA-H28D14 (Mut T1), (ii) sb-
HA+SA-CR6261 (Mut T2) and, (iii) PBS control.  Four mice were immunized per group. 
The protein antigens were diluted to 20 µg/mL in PBS (on a HA basis). Two µg of antigen 
per mouse was injected adjuvanted with Addavax on days 0 and 28. On day 42 the mice 
were bled for analysis and serum was stored at -20°C until further use.  
3.2.1.5 Serum analysis  
The day 70 serum from the three groups was assessed for endpoint titer against wild-type 
HA and against the chimeric cH5/1 HA. Briefly, 50 µL of 0.002 mg/mL HA was coated 
per well on ELISA plates overnight at 4°C in PBS. Plates were blocked with 100 µL of 5% 
BSA in PBST for 1 hr at RT. After 3x washes with PBST, plates were incubated with 50 
µL of sera diluted four-fold starting at 1:100 in 1% BSA in PBST for 1 hr at RT. After 3x 
washes with PBST, plates were incubated with a secondary HRP-conjugated anti-mouse 
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antibody (115-035-003, Jackson ImmunoResearch) for 1 hr at RT. After 3x washes with 
PBST, plates were developed with TMB substrate solution (00-2023, Thermo Fisher) for 
5 min and stopped using 160 mM sulfuric acid solution. Plates were read on a Spectramax 
i3x plate reader (Molecular devices) at 450 nm. Titers were expressed as area under the 
curve (AUC) determined using GraphPad Prism software. Appropriate controls were 
included.  
3.2.1.6 Statistical analysis  
AUC was calculated using a sigmoidal curve fitting. A minimum of three technical repeats 
were tested for all ELISAs, and the experiments were repeated at least three times with 
similar results. One-way ANOVA with post-hoc Tukey’s multiple comparison test was 
applied when indicated in the figure legend. All statistical analysis was performed using 
GraphPad Prism 8 (GraphPad Software Inc.) 
3.2.2 Results and Discussion 
3.2.2.1 Expression, purification and synthesis of Fab-tethered HA mutants 
Fig. 22 shows the scheme for the design of the tethered HA mutants. We first expressed 
the head-binding Fab H28D14 with an AviTag fused to the N-terminus of its light chain 
spaced by a flexible GGGGS linker. The avi-H28D14 Fab was expressed in mammalian 
cells and purified by IMAC followed by a refining SEC step to remove aggregates. The 
avi-H28D14 Fab was then biotinylated ex vivo and purified by desalting to remove excess 
biotin. The extent of biotinylation was determined by performing an SDS-PAGE gel shift 
assay by complexing with excess streptavidin. Next, the biotinylated Fab was mixed with 
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excess streptavidin. The streptavidin (shown in cyan in Fig. 22) was separately expressed 
and purified from bacterial inclusion bodies.  
Streptavidin has four biotin binding sites – with two sites located on each of its 
diametrically opposite binding interfaces. However, in our experience, when reacting an 
avi-tagged Fab with streptavidin, a maximum of two Fabs were able to bind (as determined 
from SDS-PAGE). A possible explanation for this unusual behavior is the steric hindrance 
from the avitag and the Fab that prevents another biotinylated moiety from binding on the 
site at the same face once one avi-tagged Fab binds. As we were interested in preferentially 
synthesizing a complex of Streptavidin with a single Fab bound, this anomaly proved 
beneficial for our approach.  
 
Figure 22. Schematic illustrating the design of Fab-tethered HA 
 
 68 
We next reacted the biotinylated Fab with an excess of streptavidin (6-fold molar excess) 
to favor the formation of a mono-Fab streptavidin conjugate with a lower proportion of bi-
Fab streptavidin conjugate. Despite the excess streptavidin used in the reaction we still saw 
the presence of up to 50% of the undesirable bi-Fab streptavidin conjugate. We used SEC 
to separate the mono-Fab streptavidin conjugate from the bi-Fab streptavidin conjugate and 
the excess streptavidin from the reaction mixture. Further, the unbiotinylated Fab was seen 
to coelute with the desired mono-Fab streptavidin conjugate post–SEC. An additional 
anion exchange chromatography step was performed to remove the unbiotinylated Fab 
fraction.  
The SA-Fab complex (shown in Fig. 22 top right) was then mixed with the biotinylated 
trimeric HA expressed and purified from insect cell cultures. The SA-Fab was added in a 
1.2:1 ratio with respect to HA to ensure complete shielding. Fig. 22 shows the final product 
with the Fab tethered to HA via streptavidin, to completely shield the head domain.  
A similar approach was used to design the stalk shielding tether (SA-CR6261) that was 
mixed with the HA mutant biotinylated near the stalk region (sb-HA). The linker 
connecting the Fab and the streptavidin was 5x or 10x repeats GGGGS, encoded 
genetically in the Fab between the avitag and the Fab sequence. In absence of a crystal 
structure for the H28D14 Fab binding to HA, we relied on the approximate distance 
between the biotin site on HA (where streptavidin would conjugate to) and the epitope for 
the H28D14 Fab, to estimate the length of linker.  
3.2.2.2 Characterization of Fab-tethered shields by SDS-PAGE and analytical SEC  
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Fig. 23A shows an SDS-PAGE image for the components used in the synthesis of the Fab-
tethered HA. The first lane shows the ladder; the second lane shows the biotinylated HA 
(which was biotinylated in situ during expression); the third lane shows the streptavidin-
Fab tether; the fourth lane shows a mixture of HA with the tether. The bands corresponding 
to HA and the tether alone disappear in the mixture and move higher on the gel indicating 
the formation of the desired product i.e. HA bound to the SA-Fab shield. The band for HA 
on SDS-PAGE corresponds to a single protomer as the trimer falls apart in the presence on 
SDS. 
 
Figure 23. Characterization of Fab-tethered head shielded HA. (A) SDS-PAGE 
image showing: HA, head-shield, and the mixture. (B) Overlay of chromatograms for 
Fab-tethered head-shielded HA competed with monomeric Fab with a 5xGGGGS 
linker. (C) Overlay of chromatograms for constructs with a 10xGGGGS linker 
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Next we wanted to determine if the Fab-tethered shields were able to shield the antigenic 
site on the head domain that the Fab shields. Thus, we performed competitive binding 
assays and analyzed by SEC the ability of the Fab-tethered shield to prevent binding of a 
competing monomeric Fab. Fig. 23B shows an overlay of chromatograms for the Fab-
tethered head-shielded HA, using a 5x GGGGS linker in the Fab-SA conjugate, when 
competed with monomeric Fab. The blue chromatogram is for the biotinylated HA alone 
with a peak at ~11.4 mL. When mixed with the SA-H28D14 shield, the peak shifts to the 
left ~8.2 mL (as shown by the purple chromatogram). When competed with monomeric 
Fab we see a near-complete blocking of the competing Fab, as suggested by unaffected 
peak intensity for the HA+SA-H28D14 conjugate (as shown by the gray chromatogram). 
The yellow chromatogram corresponds to the monomeric competing Fab alone peaking at 
~15.5 mL. We also confirmed the ability of the head-shielded sample (HA+SA-H28D14) 
to bind to a stalk-binding Fab (CR6261), shown by the orange chromatogram. The increase 
in intensity of the peak ~8-8.5 mL suggests binding of the stalk-binding Fab to the head-
shielded sample. Fig. 23C shows a similar overlay of chromatograms for the Fab-tethered 
head-shielded HA, using a 10x GGGGS linker in the Fab-SA conjugate (SA-H28D14’). 
Like for the head shield with a 5x GGGGS linker (Fig. 23B), the shield with a 10x GGGGS 
linker was effective at blocking binding to the competing monomeric H28D14 Fab.  
We similarly designed a stalk-shielded version of HA by tethering a stalk-binding Fab 
(CR6261) to the C-terminus of HA via streptavidin, using a similar strategy. We found 
comparable results in the analytical SEC characterization for the two linker lengths tested 
(5x or 10x of GGGGS) for both the head and stalk shields. Hence we proceeded with the 
shorter 5x GGGGS linker for our animal experiment.  
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Next, to understand if this shielding effect translates to the suppression of the head or stalk 
response in vivo we proceeded with an animal study with the HA antigens designed by this 
approach. In parallel, we also designed an alternative strategy to tether the Fab to HA that 
was less elaborate in synthesis requiring fewer chromatography steps. This alternative 
strategy involves the expression of the shielding Fab fused to a monomeric Rhizavidin in 
a single step.  
3.2.2.3 Immunization with Fab-tethered HA detects a chimeric HA 
Fig. 24A (left) shows the head-shielded HA obtained by tethering the head specific Fab to 
HA via streptavidin (referred to as Mut T1). As a control, we similarly designed a stalk-
 
Figure 24. Immunization and antibody titer data for Fab-tethered HA. (A) 
Cartoon showing the head-shielded and stalk-shielded HA mutants (B) Immunization 
schedule in mice (C) Day 42 serum antibody titers data for the immunized groups 
tested against wtHA and cH5/1 HA. (**p<0.01, ns – not statistically significant, 





shielded HA by tethering a stalk-specific Fab CR6261 to HA via streptavidin, as shown in 
Fig. 24A (right) (referred to as Mut T2). We immunized naïve mice with these two antigens 
or PBS (control). The immunization schedule is shown in Fig. 24B.  
To understand if the immune response had been refocused we expressed and purified a 
cH5/1 chimeric HA [84] with the head domain sequence from an H5N1 virus and the stalk 
domain sequence from the H1N1 virus – the one that our HA immunogens were based on. 
The chimeric cH5/1 recombinant HA protein should selectively bind to stalk antibodies 
only – allowing us to dissect the specificity of the elicited antibodies for the immunized 
samples.  
Fig. 24C shows the day 42 serum antibody titers when probed against wtHA (left cluster) 
or against cH5/1 (right cluster). The cartoon for cH5/1 HA is shown in Fig. 24C with the 
head epitopes highlighted in yellow (as opposed to red for H1) to indicate the head domain 
from H5. When probing titers against wtHA, both Mut T1 and Mut T2 bind. However, 
when probing titers against the cH5/1 HA (which should detect binding of stalk antibodies 
only), the binding of Mut T2 is close to baseline – suggesting that the stalk shielding 
suppressed the elicitation of stalk antibodies to an appreciable extent. However, the head-
shielded mutant Mut T1 was able to detect the chimera suggesting the presence of stalk 
antibodies upon immunization with Mut T2. 
The recombinant wtHA used for the titer experiments was expressed with a T4 foldon 
trimerization domain and also a hexahistidine tag. The HA samples that were used for 
immunization were also expressed with the T4 foldon trimerization domain and a 
hexahistidine tag. Hence, antibodies against the trimerization domain and the hexahistidine 
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tag would also be present in the serum. In contrast, the cH5/1 (used for titer experiments) 
was expressed with an alternate trimerization domain (GCN4) and an alternate purification 
tag (Strep II® tag). One question this result raises is the observed difference in titers for 
Mut T1 against wtHA and cH5/1. If the head region was successfully shielded, then the 
titers against wtHA and cH5/1 should be similar. This difference can be explained by the 
presence of antibodies in Mut T1 serum elicited to the trimerization domain and 
hexahistidine tag. These antibodies can bind to wtHA (which has the similar trimerization 
domain and purification tag) but not to cH5/1 HA. In other words, Mut T2 titers against 
cH5/1 represent binding of antibodies exclusively to the stalk domain whereas those to 
wtHA include binding to the stalk domain as well as the trimerization domain and the 
hexahistidine tag.  
Based on these promising preliminary results we are working on evaluating the ability of 
the serum from these immunized samples to inhibit viral infection in a microneutralization 
assay. This assay should provide more insights into whether the head-shielded group is 
more effective at neutralizing a heterologous viral strain when compared to the control 
stalk-shielded group.  
3.2.2.4 Alternative approach to tethered shielding using rhizavidin  
The approach we described above for tethering a Fab to HA so as to shield its head domain 
has shown promise in an initial animal study. However, the approach to synthesize the head 
shields is elaborate involving multiple steps of chromatography. As a result, we parallelly 
developed a relatively simpler approach to achieve the same shielding effect.  
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Our alternative strategy involves the use of a monomeric engineered rhizavidin [102] as a 
substitute for streptavidin in our existing scheme. One advantage of this approach is that 
because this version of rhizavidin (eRA) is a monomer (as opposed to a tetrameric 
streptavidin), we could co-express eRA with the Fab, spaced by a linker, in a single step in 
mammalian cells. Further, eRA is smaller and more compact (15kDa vs. 60kDa for 
streptavidin), hence the undesirable response to the avidin protein should be significantly 
lower.  
Fig. 25A shows the synthesis scheme for the eRA-based tether. The head-binding Fab was 
expressed by genetically fusing the eRA DNA sequence spaced by an appropriate linker. 
For this initial test system we chose 5x repeats of GGGGS as the linker based on our 
estimates as discussed in the previous section. When mixed with the biotinylated HA, the 
eRA based tether should allow the Fab to tether to HA, essentially shielding the head 
domain, as shown in Fig. 25A (far right). 
We next tested the ability of the eRA-H28D14 tether to block binding of head antibodies 
to HA by ELISA. Fig. 25B shows the ELISA results. Each cluster corresponds to the set 
of antigens tested against a particular antibody as indicated in the bottom. We tested the 
head specific antibodies for three of the four head antigenic sites (Sa, Sb and Ca) and to 
the stalk binding antibody CR6261 (shown in blue). The avitag insertion on HA to allow 
biotin incorporation and further conjugation to the shield was made between residues V77 
and R78, which are located in the Cb site. This insertion by itself disrupted binding of the 
Cb antibody – and so results for that region have not been included in the data set. For each 
of the antibodies tested, the first bar corresponds to binding to the biotinylated HA; the 
second bar for binding to the head shielded HA via eRA-based Fab tethering; the third bar 
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corresponds to a complex of HA and the H28D14 Fab alone (untethered); and the fourth 
bar is for BSA background. As can be seen, for all three head antibodies the binding drops 
 
Figure 25. Design and characterization of eRA based head-shields for HA. (A) 
Synthesis scheme for eRA-H28D14 Fab tether bound to biotinylated HA (B) ELISA 
result showing binding of head and stalk antibodies to HA and the head shielded HA 
based on eRA Fab tethering (C) Overlay of SEC chromatograms for a competitive 
binding assay of monomeric Fab to the HA tethered Fab. (*p<0.05, ****p<0.0001, ns 
– not statistically significant, determined by a one-way ANOVA with post-hoc 




for the head shielded HA as expected. Further, the binding of the head antibodies to the 
untethered Fab control is comparable to binding to HA alone – suggesting that the blocking 
is specifically a result of tethering the Fab to HA. The stalk antibody binds to the head 
shielded sample as it does to HA alone, as expected.  
We next tested the ability of the eRA based Fab tether to block binding to an excess of 
competing head binding Fab in solution. Fig. 25C shows an overlay of SEC chromatograms 
run for the eRA-H28D14 tethered head shielded HA when competed with a 10-fold molar 
excess of monomeric competing H28D14 Fab. The blue chromatogram is for the 
biotinylated HA alone with a peak at ~11.5 mL. When mixed with the eRA-H28D14 shield, 
the peak shifts to the left ~9.5 mL (as shown by the orange chromatogram). This peak for 
the complex is unimodal suggesting the absence of any rosettes. When competed with a 
10-fold molar excess of monomeric Fab H28D14 we do not see a shift in the peak at 9.5 
mL - suggesting the tethered Fab is strongly bound to HA (gray chromatogram). The 
yellow chromatogram corresponds to the monomeric competing Fab alone peaking at 
~15.5 mL. 
These initial results for the alternate tethering strategy are promising. We will in the near 
future evaluate the ability of these eRA based Fab-tethered head shielded mutants to 
selectively suppress the immune response to the head domain of HA, by performing an 
animal study in mice.  
3.3 Shielding the Hemagglutinin head using soluble-biFab shields 
Fig. 26 shows a schematic of the proposed bivalent-Fab shielding approach to shield the 
head domain of HA. Fig. 26B (top) shows a cartoon of a ligand-receptor pair where the 
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monomeric ligand is analogous to a Fab binding to its antigen partner. Instead, if the ligand 
is multivalent - such that multiple copies of the ligand bind to multiple copies of the 
receptor, the binding avidity can be greater by orders of magnitude [59, 103-106]. The 
association of one ligand with one receptor increases the local concentration of the other 
ligand enabling a significant increase in the binding avidity. The cartoon in Fig. 26B 
(bottom) shows a case where the ligand in purple is dimerized with another ligand in green 
allowing multivalent binding to the receptor.  
Fig. 26A (top) shows the binding of a monomeric Fab (shown in shades of purple) to the 
tip of the HA head. This case is similar to the experiment performed by Angeletti et al.[62], 
where on immunizing mice with this complex of an Sb site binding Fab with HA, the 
 
Figure 26. Schematic for a bi-Fab shielding the head domain of HA. (A) Top: HA 
bound to a Fab (purple) that binds to the tip of the head region; Bottom: A bi-Fab 
bound to HA (B) Top: Cartoon showing a ligand receptor pair (purple and gray 




resulting sera showed selective suppression of an immune response to the Sb antigenic site 
on HA [62]. However, there was still a residual response to the head domain of HA as the 
other antigenic sites were left exposed, as shown by the incompletely shielded red epitopes 
in Fig. 26A (top).  
To build on this model, we proposed to design a bivalent Fab by dimerizing the Sb specific 
Fab (shown in purple) to another Fab (shown in green) that binds to the Cb antigenic site 
at a site lower down on the head domain. The bi-Fab shield would collectively block the 
head domain more completely as can be seen in the proposed scheme in Fig. 26B (bottom). 
Moreover, the binding avidity of the bi-Fab for HA should be higher when compared to 
the affinities of the individual monomeric Fabs, because of the increased binding avidity 
through multivalency. The stalk region would still be accessible in this engineered “head-
shielded” HA, which would allow the immune response to be refocused to the conserved 
stalk epitopes. 
3.3.1 Materials and Methods 
3.3.1.1 Hemagglutinin Expression and Purification 
Influenza Hemagglutinin (HA: strain A/Puerto Rico/8/1934 H1N1) was expressed and 
purified as previously described [100]. The DNA for hemagglutinin (PDB ID: 1RU7) was 
optimized for insect cell expression and synthesized and cloned into pFastBacDual vector 
by GeneUniversal Inc., Delaware, under the p10 promoter. A c-myc tag (EQKLISEEDL) 
was inserted at the C-terminus of the HA sequence followed by a trimerization domain 
from T4 phage fibritin followed by a hexa-histidine tag. The HA protein was expressed 
and purified from insect cells as described in the previous section. 
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3.3.1.2 Design and synthesis of soluble-biFab shields 
The DNA encoding light and heavy chain variable regions (VL and VH resp.) for HA head 
specific Fabs H28D14 and H35C12 (sequences generously provided by Dr. Jonathan 
Yewdell, NIH [62]) were optimized for mammalian expression and synthesized and cloned 
in TGEX-LC and TGEX-FH vectors respectively by Gene Universal Inc., Delaware. 
Similarly, the VL and VH regions for a HA stalk specific Fab CR6261 (PDB ID: 3GBN) 
and the anti-c-myc Fab 9E10 (PDB ID: 2OR9) were cloned in TGEX-LC and TGEX-FH 
vectors. The SpyCatcher-SpyTag system [48] was used to dimerize the Fabs. We used a 
truncated version of SpyCatcher (SpyCatcherdN) with the N-terminal region, which has 
been shown to be redundant, deleted [107]. The DNA encoding SpyCatcherdN was 
optimized for mammalian expression and cloned upstream of the light chains of Fabs 
H35C12 and CR6261 spaced by either 5x or 10x repeats of GGGGS. A Spytag was inserted 
upstream of the light chain of Fab H28D14 and heavy chain of Fab 9E10 by SDM to result 
in Fabs henceforth termed as spH28D14 and sp9E10. A hexa-histidine tag was 
incorporated at the C-terminus of the heavy chain of all Fabs for purification purposes. 
The SpyCatcher-fused and SpyTagged Fabs were expressed in HEK293F suspension cells 
using the ExpiFectamine™ 293 transfection kit (A14524, Gibco) using the manufacturer’s 
protocol. After expression, the cell culture supernatants were thoroughly dialyzed against 
PBS and Fabs were purified by IMAC followed by SEC on a Superdex 75 Increase 10/300 
GL column (GE Healthcare, 29-1487-21) in PBS buffer. The SEC refining step removes 
aggregates if any. Next, the Fabs were quantified by a BCA assay and reacted to allow 
dimerization of the appropriate Fab pair by isopeptide bond formation between Spycatcher 
and Spytag. A 50% molar excess of the SpyTagged Fab was reacted to its SpyCatcher fused 
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Fab partner (H35C12 dimerized with H28D14 and CR6261 with 9E10). The extent of 
reaction completion was confirmed by SDS-PAGE and the “biFab” was separated from the 
unreacted monomeric Fabs by SEC (HiLoad 16/600 Superdex 200 column, GE Healthcare) 
in PBS buffer. The purified biFabs were concentrated, quantified using BCA assay, and 
stored at 4°C until further use. 
The head biFab shield, synthesized by dimerizing Fabs H28-D14 and H35-C12, when 
mixed with HA results in a head-shielded version of HA - referred to as MutS1. The stalk 
biFab shield, synthesized by dimerizing Fabs CR6261 and 9E10, when mixed with HA 
results in a stalk-shielded version of HA – referred to as Mut S2. The shields in both cases 
were mixed in a 1.2:1 stoichiometric ratio with HA, with the shield in excess. 
3.3.1.3 Characterization of biFab shields by ELISA and analytical SEC 
Purified antibodies H2-6A1, H28E23, H17-L2, H18-L9 and H18-S48 were generously 
provided by Dr. Jonathan Yewdell, NIH [62]. The DNA encoding light and heavy chain 
variable regions (VL and VH resp.) for other HA head specific antibodies - H28-D14 and 
H35-C12 (sequences generously provided by Dr. Jonathan Yewdell, NIH) and stalk-
specific antibodies – C179 (PDB ID: 4HLZ) and CR6261 (PDB ID: 3GBN), were 
optimized for mammalian expression, synthesized and cloned in TGEX-LC and TGEX-
HC vectors by Gene Universal Inc. (Newark, DE). The antibodies were expressed in 293F 
cells and purified using the HiTrap MabSure Select™ column (29-0491-04, GE 
Healthcare) on an AKTA Start system following the manufacturer’s protocol. These 
antibodies were further labelled with biotin for ELISA characterization purposes using EZ-
Link™ Sulfo-NHS-LC-Biotin (A39257, Thermo Scientific) following manufacturer’s 
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recommendations and purified by desalting. A FLAG tag was inserted at the C-terminus of 
the heavy chain for Fabs H28-D14, H35-C12 and CR6261via SDM and the FLAG-tagged 
Fabs were expressed and purified as described in the previous section. 
The designed antigens were characterized by ELISA to confirm the ability of the biFab 
shields to block recognition to desired head epitopes. The biFab shield was mixed with HA 
in a 1.2:1 stoichiometric ratio with the shield in excess. For the ELISA, 50 µL of 0.002 
mg/mL of the antigen solution (on a HA basis) was coated per well on ELISA plates 
(Maxisorp NUNC, Thermo Scientific) overnight at 4°C in PBS. Plates were blocked with 
100 µL of 5% Bovine serum albumin (BSA) (12659, EMD Millipore) in PBST (PBS with 
0.05% Tween-20) for 1 hr at RT. After 3x washes with PBST, plates were incubated with 
50 µL of primary antibody solutions (biotinylated antibodies or FLAG-tagged Fabs) in 1% 
BSA in PBST for 1 hr at RT. After 3x washes with PBST, plates were incubated with 
secondary antibody (either Streptavidin or anti-FLAG Ab conjugated to HRP) for 1 hr at 
RT. After 3x washes with PBST, plates were developed with TMB substrate solution (00-
2023, Thermo Fisher) for 5 min and stopped using 160 mM sulfuric acid solution. Plates 
were read on a Spectramax i3x plate reader (Molecular devices) at 450 nm. Experiments 
were performed in triplicates. 
SEC shifts were performed with the biFab shielded HA antigens by competing with the 
corresponding monomeric Fabs or Abs. All SEC chromatograms were run on Superdex 
200 Increase 10/300 GL column (GE Healthcare, 28-9909-44) in PBS buffer using 5µg of 
antigen (on a HA basis). Competing Fabs or Abs were run in a 1.2:1 stoichiometric excess 
with the biFab shielded antigen. Chromatograms were recorded using UV205 and overlaid 
for comparison. 
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3.3.1.4 Immunizations in mice  
BALB/c mice were immunized with the engineered HA mutants at the Rafi Ahmed Lab 
(Emory University, GA). Samples included were: (i) wtHA, (ii) Head-shielded HA (Mut 
S1) and, (iii) Stalk-shielded HA (Mut S2). 5 mice were immunized per group. The protein 
antigens were diluted to 1000 µg/mL in PBS (on a DIII basis). 5 µg of antigen per mouse 
was injected adjuvanted with AddaVax on days 0, 28, 56. On day 56 the mice were bled 
for analysis and serum was stored at -20°C until further use.  
3.3.1.5 Serum analysis 
The day 56 serum from the three groups was assessed for endpoint titer against wild-type 
HA and against the chimeric cH5/1 HA by ELISA, as described before.  
3.3.1.6 Statistical analysis  
AUC was calculated using sigmoidal curve fitting. A minimum of three technical repeats 
were tested for all ELISAs, and the experiments were repeated at least three times with 
similar results. One-way ANOVA with post-hoc Tukey’s multiple comparison test was 
applied when indicated in the figure legend. All statistical analysis was performed using 
GraphPad Prism 8 (GraphPad Software Inc.) 
3.3.2 Results and Discussion 
3.3.2.1 Expression, purification and synthesis of shielded HA mutants 
Fig. 27 shows the scheme for the design of the bi-Fab shields. We first expressed a version 
of the Fab H35C12 (Fab1, shown in green) with a SpyCatcher fused to the N-terminus of 
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its light chain spaced by a linker with either 5x or 10x repeats of GGGGS. The SpyCatcher 
used here was a version with an N-terminal fragment deleted, which has been shown to be 
less immunogenic than the full length SpyCatcher, yet retaining the functionality [107]. 
The SpyCatcher-fused Fab1 was expressed in mammalian cells and purified by IMAC 
followed by SEC to remove aggregates. We then expressed and purified a version of the 
Fab H28D14 (Fab2, shown in purple in Fig. 27) with a SpyTag fused to the N-terminus of 
its light chain. After individual purifying the two Fabs, these were reacted to one another 
with the Fab2 with a SpyTag (SpyTag-H28D14) in a 1.2:1 ratio wrt to the Fab fused to the 
SpyCatcher (SpyCatcher-linker-H35C12). The SpyCatcher reacts with the SpyTag 
spontaneously forming an isopeptide bond and thus conjugating the two Fabs together 
resulting in a biFab. This biFab shield was then mixed with HA expressed and purified 
 




from insect cells. The resulting complex is the desired product (Mut S1) where the head 
domain of HA is shielded by the biFab shield.  
3.3.2.2 Characterization of bi-Fab head shields by SDS-PAGE, ELISA and analytical 
SEC 
Fig 28A is an SDS-PAGE image showing the various components used for the bi-Fab head 
shielded HA. The first lane shows the ladder. The second lane shows HA alone, the trimer 
 
Figure 28. Characterization of bi-Fab HA head shields. (A) SDS-PAGE image 
showing HA, individual Fabs, Fab1 and Fab2, and the bi-Fab (B) SEC shift showing 




of which dissociates in presence of SDS and appears at ~65 kDa corresponding to a single 
protomer. The third lane shows the Fab1 (H35C12 Fab fused to Spycatcher) and the fourth 
lane shows the Fab2 (SpyTagged H28D14 Fab). The last lane shows the purified bi-Fab 
product obtained on reacting the two Fabs followed by purification on SEC.  
Next we wanted to confirm that the bi-Fab shield binds to HA as expected. Because this 
binding is non-covalent, a gel shift on SDS-PAGE is not appropriate. Hence, we performed 
an analytical SEC shift to confirm the binding of the shield to HA. Fig. 28B shows an 
overlay of chromatograms run for HA alone (in blue), bi-Fab shield (in orange) and a 
stoichiometric mixture of HA and the bi-Fab shield (in gray). The peak for HA shifts from 
~12 mL to ~10 mL when the bi-Fab shields bind to HA. 
Next, it was important to evaluate the ability of the bi-Fab shield bound to HA to block 
access to the head epitopes. Thus, we performed an ELISA and probed binding of various 
head antibodies binding to the discrete antigenic sites to wtHA and the head-shielded 
version of HA. This head shielded mutant of HA will be referred to as Mut S1. Antibodies 
H2-6A1 (Sa), and H18-L9 (Ca) and Fabs H28-D14 (Sb) and H35-C12 (Cb) were used for 
the assay [62]. Fig. 29A shows the ELISA results for the binding of head specific antibodies 
and a stalk binding antibody to wtHA and Mut S1 with either 5x or 10x repeats of GGGGS 
between the bi-Fab shield. Each cluster of bars corresponds to the antibody used to probe 
binding. The first bar in each case shows binding of that antibody to wtHA, the second bar 
shows binding to Mut S1 with 5x linker, the third bar shows binding to MutS1 with 10x 
linker and the fourth bar in gray is a BSA control. As expected, we see that the binding of 
all antibodies to HA reduces significantly in the presence of the bi-Fab shields. We did not 
see a difference in the effect of shielding ability between the 5x and 10x linker lengths 
 86 
tested. Thus, we chose to proceed with the 5x linker for further experiments. This data 
suggests that the bi-Fab shield is efficient at blocking access to all antigenic sites of the 
head domain. Further, we also probed binding of a stalk binding antibody CR6261 [108] 
to wtHA and the head-shielded Mut S1 (either 5x or 10x linker based) and as shown by the 
blue bars, the binding of the stalk antibody to the Mut S1 is comparable to its binding to 
wtHA. This result confirms the ability of bi-Fab shields to selectively block the head 
domain of HA while retaining binding to the stalk domain.  
Furthermore, we were also interested in understanding if the shielding of the head 
antibodies is dependent on the dose of the bi-Fab shield. To study this we performed ELISA 
against each of the 4 head-specific antibodies and tested those against wtHA alone and 
against HA with increasing doses of the bi-Fab shield with the 5x linker. The results for 
this dose-response ELISA are shown in Fig. 29B. We tested a series of ratios of bi-Fab:HA 
– 0.1, 0.2, 0.4, 0.8 and 1.2:1. We also tested a sample where the HA was shielded with a 
mixture of monomeric individual Fabs that were not tethered to each other. This sample is 
important because it would verify the importance of dimerizing the two Fabs together and 
emphasize the importance of our strategy. For each of the 4 antibodies tested (H2-6A1 
(Sa), H18-L9 (Ca), H28-D14 (Sb) and H35-C12 (Cb)), we saw a dose-response type curve 
where the extent of blocking increases with an increase in the dose of the bi-Fab (shown 
as bars in various shades of red). At sub-stoichiometric amounts of the added shield, the 
blocking is incomplete. A ratio of 1.2:1 was determined to be effective at shielding for 
most antibodies and we thus chose to proceed with this ratio of bi-Fab:HA for our following 
experiments. Interestingly, for all four antibodies, the sample that was “shielded” with a 
monomeric mixture of the two Fabs (yellow bar), we do not see blocking of any of the four 
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antibodies. The signal for this sample is comparable to the binding to wtHA, suggesting 
that dimerizing the Fabs together increases the affinity of either Fab to HA.  
 
Figure 29. Characterization of bi-Fab head shield by ELISA. (A) Binding of site-
specific anti-HA head (in red) and stalk (in blue) antibodies to wtHA and head-
shielded HA (Mut S1 with 5x or 10x linker between the bi-Fab shield) (B) Binding of 
head-specific antibodies to HA shielded with increasing doses of the bi-Fab head 
shield. (***p<0.001, ****p<0.0001 determined by a one-way ANOVA with post-hoc 




We next tested the ability of the bi-Fab head shield to block binding to an excess of 
competing monomeric Fabs in solution. Fig. 30 shows an overlay of SEC chromatograms 
run for the bi-Fab head shielded HA when competed with a 5-fold molar excess of 
monomeric competing Fabs H28D14 and H35C12. The blue chromatogram is for wtHA 
alone with a peak at ~12 mL. The bi-Fab shield alone exhibits a peak at ~13 mL shown by 
the orange chromatogram. The bi-Fab head-shielded HA is shown by the green 
chromatogram with a peak at ~9.5 mL. Next, when the bi-Fab head shield mixed with HA 
 
Figure 30. Characterization of bi-Fab head-shielded HA by competitive 
analytical SEC. Top: Cartoon showing biFab head-shielded HA competed with the 
monomeric Fabs. Bottom: Overlay of SEC chromatograms for the competitive 




was further competed with a 5-fold molar excess of a mixture of monomeric Fabs H28D14 
and H35C12 (shown by the gray chromatogram) we do not see the bi-Fab shield getting 
displaced as seen by the absence of a peak at 13 mL. The chromatogram in purple shows 
the bi-Fab head-shielded HA mixed with a stalk binding Fab CR6261, the peak for which 
shifts further to the left suggesting the ability of a stalk antibody to bind to the head-
shielded HA. This result suggests that the bi-Fab shield is bound to HA even in the presence 
of excess competing Fabs. The yellow chromatogram corresponds to the mixture of the 
two monomeric competing Fabs with their individual peaks at ~15.5 mL and ~17mL.  
We found comparable results in the characterization (by ELISA and analytical SEC) for 
the two linker lengths tested (5x or 10x of GGGGS) for both the head and stalk bi-Fab 
shields. Hence we proceeded with the shorter 5x GGGGS linker for our animal experiment. 
Having characterized the bi-Fab shields for their ability to block the head domain of HA, 
we next evaluated their ability to suppress the immune response to the head domain upon 
immunization in naïve mice. 
3.3.2.3 Immunization with bi-Fab shielded HA detects chimeric HA 
Fig. 31A shows a cartoon for the samples immunized for the animal study. The head-
shielded HA with the bi-Fab shielding the head domain is referred to as Mut S1. As a 
control, we similarly designed a stalk-shielded HA by designing a bi-Fab specific to the 
stalk domain by dimerizing the stalk specific Fab CR6261 (shown in orange) with an anti-
c-myc binding Fab 9E10 (shown in cyan). A c-myc tag introduced at the C-terminus of HA 
allows binding of the stalk bi-Fab to HA. This stalk-shielded mutant of HA is referred to 
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as Mut S2. We also included a wtHA control for the experiment. The immunization 
schedule is shown in Fig. 31B.  
To understand if the immune response had been refocused we expressed and purified a 
cH5/1 chimeric HA [84] with the head domain sequence from an H5N1 virus and the stalk 
domain sequence from the H1N1 virus – the one that our HA immunogens were based on. 
The chimeric cH5/1 recombinant HA protein should selectively bind to stalk antibodies 
only – allowing us to dissect the specificity of the elicited antibodies for the immunized 
samples.  
Fig. 31C shows the day 56 serum antibody titers when probed against wtHA (left cluster) 
or against cH5/1 (right cluster). The cartoon for cH5/1 HA is shown in Fig. 31C with the 
head epitopes highlighted in yellow (as opposed to red for H1) to indicate the head domain 
 
Figure 31. Immunization and antibody titer data for bi-Fab shielded HA. (A) 
Cartoon showing the head-shielded and stalk-shielded HA mutants (B) Immunization 
schedule in mice (C) Day 56 serum antibody titers data for the immunized groups 




from H5. When probing titers against wtHA, all three immunized groups – wtHA, Mut S1 
and Mut S2 bind. However, when probing titers against the cH5/1 HA (which should detect 
binding of stalk antibodies only), the binding of Mut S2 is close to baseline – suggesting 
that the stalk shielding suppressed the elicitation of stalk antibodies to an appreciable 
extent. However, the head-shielded mutant Mut S1 was able to detect the chimera 
suggesting the presence of stalk antibodies upon immunization with Mut S1. Two of the 
four mice immunized with Mut S1 did not respond to the immunization with HA antigens 
even after 2 doses. This was unusual, but the trends we see for the two mice that did respond 
are as expected.  
As discussed in the previous section, the difference in titers observed for MutS1 against 
wtHA and cH5/1 is likely from antibodies elicited against the trimerization domain and the 
hexahistidine purification tag. The recombinant wtHA used for the titer experiments was 
expressed with a T4 foldon trimerization domain and also a hexahistidine tag. The HA 
samples that were used for immunization were also expressed with the T4 foldon 
trimerization domain and a hexahistidine tag. Hence, antibodies against the trimerization 
domain and the hexahistidine tag would also be present in the serum. In contrast, the cH5/1 
(used for titer experiments) was expressed with an alternate trimerization domain (GCN4) 
and an alternate purification tag (Strep II® tag).  
Based on these promising preliminary results we are working on evaluating the ability of 
the serum from these immunized samples to inhibit viral infection in a microneutralization 
assay. This assay should provide more insight into whether the head-shielded group is more 
effective at neutralizing virus when compared to the control stalk-shielded group. 
However, it is important to note here that unlike naïve mice that were used for this 
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immunization experiment, humans are usually exposed to influenza virus, either through 
vaccination or infection. It has been hypothesized that the low levels of stalk-reactive 
antibodies could effectively be boosted to protective levels by immunizing with a head-
shielded construct as ours [84]. Hence, the efficacy of our engineered head-shielded HA 
construct can be better evaluated over immunizing with wtHA alone, in the context of 
preexisting immunity to influenza virus.  
In summary, the preliminary results with the bi-Fab shielded mutants suggest refocusing 
of the immune response and we have shown that the head-shielded mutant of HA (Mut S1) 
elicits stalk-binding antibodies as shown by binding of serum antibodies to the chimeric 
cH5/1 HA. As a part of future work, we will evaluate the ability of these serum antibodies 
to neutralize infection in a microneutralization assay.  
3.4 Conclusion and Future Perspectives 
We present an approach to selectively suppressing the immune response on an antigen 
using antibody fragments as shielding agents. Because the binding of the Fab to its antigen 
partner is non-covalent, we have developed two approaches to enhance the interaction of 
the Fab-antigen complex. We have explored this immunofocusing approach in the context 
of shielding the immunodominant yet variable head domain of HA of influenza virus. The 
first approach involves tethering the Fab to the antigen using avidin-like proteins as the 
tethering agents. We have shown preliminary animal data that suggests suppression of the 
immune response towards the desired region of HA. The second approach involves 
designing bivalent Fabs to shield the head domain of HA more completely than achieved 
by binding of a single Fab. Further, dimerizing the Fabs together are better at shielding the 
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head domain than a mixture of the two monomeric Fabs. We have similarly shown 
preliminary evidence suggesting the ability of these bi-Fab shields in suppressing the 
immune response towards the desired region of HA.  
For future studies, we are interested in evaluating the ability of serum antibodies obtained 
on immunizing with our Fab-shielded HA constructs to neutralize infection by a 
microneutralization assay. Further, we are also interested in studying the efficacy of our 
vaccine constructs in mice with preexisting immunity to influenza – which is a more 
realistic model for testing.  
Strategies developed and discussed in this section can also be extended to engineer antigens 
from other infectious diseases where focusing the immune response to selected regions of 
the antigen can result in broad immunity. Our lab is currently exploring to extend this 
approach to engineer the Fusion protein (F) of respiratory syncytial virus so as to refocus 
the response towards its broadly protective epitopes.  
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CHAPTER 4. SUPPRESSING THE ELICITATION OF 
NON-NEUTRALIZING ANTIBODIES FOR DOMAIN III 
(DIII) OF ZIKA VIRUS ENVELOPE (E) PROTEIN 
USING FABS AS SHIELDS 
4.1 Introduction 
Zika Virus (ZIKV), is a flavivirus that has emerged as a global public health concern 
because of its ability to cause severe congenital disease [109]. The virus (Fig 32A) contains 
three structural proteins – capsid (C), pre-membrane (prM) and envelope (E) – of which E 
 
Figure 32. ZIKA virus and its immunogenic surface Envelope protein. (A) ZIKV 
showing its three structural proteins – Capsid (C), pre-membrane (prM) and envelope 
(E). (B) Structure of E protein dimer with its three domains shown in different colors. 
(C) Domain III (DIII) of E protein in blue with three antibodies binding to spatially 
distinct regions docked on its structure. Figure adapted from Heinz et al., 2017 [111] 
& Zhao et al., 2017 [115] with permission 
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mediates viral assembly, attachment, entry and fusion [110, 111]. This E protein is divided 
into three domains: a central β-barrel domain (domain I (DI)), an extended dimerization 
domain (DII), and an immunoglobulin-like segment (DIII) [110]. Fig 32B shows a 
structure of E protein dimers in a herringbone pattern as it lays relatively flat against the 
lipid envelope on the viral particles. The E protein has been shown to be the primary target 
of neutralizing antibodies for many flaviviruses. In particular, DIII of E protein is an 
attractive target for protective immunity because: it has been implicated in the entry of 
viruses into host cells and has been shown to be a target for protective immunity [112-114].  
Zhao et al. [115] generated a panel of antibodies against ZIKV E DIII to gain insights into 
epitopes that are recognized by neutralizing antibodies. They found that these antibodies 
recognized three spatially distinct epitopes on DIII. Fig 32C shows the structure of DIII in 
blue, docked with a representative antibody from each of the three classes. Antibody ZV67 
(shown in magenta in Fig 32C) resulted in reduced viremia and complete protection of 
mice from a lethal ZIKV infection in a passive transfer experiment [115]. ZV67 binds to 
the “so-called” lateral ridge (LR) epitope on DIII, which is the most accessible in the 
context of a mature virion as seen in Fig 33 in magenta. Interestingly, DIII-LR-binding 
mAbs against other flaviviruses e.g., West Nile Virus [113], Dengue Virus serotype-1 
[114], or Dengue Virus serotype-2 [116], also protected animals against lethal infection 
with those viruses. 
In contrast to the neutralizing ZV67 antibody, ZV48 and ZV2 (shown in cyan and green 
respectively in Fig 32C) recognized cryptic epitopes on DIII, which were not predicted to 
be accessible on the mature virion [117, 118]. ZV48 showed reduced neutralizing activity 
compared to ZV67, whereas ZV2 was found to be non-neutralizing [115]. The 
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neutralization trends correlated with the functional avidities of these antibodies for purified 
ZIKV subviral particles: ZV67 bound more avidly than ZV2. Even at the highest 
concentrations tested, ZV2 failed to saturate binding to the ZIKV subviral particles. 
Antibody-mediated neutralization of flaviviruses requires engagement of a threshold 
number of antibody molecules to the virion. For a potently neutralizing West Nile Virus 
antibody, this threshold has been estimated to be ~30 antibody molecules per virion [119]. 
In this context, two factors are important for neutralization: antibody affinity for the epitope 
and epitope accessibility. Non-neutralizing antibodies (e.g., ZV2) elicited on immunization 
with DIII are undesirable because they bind to poorly accessible (or cryptic) epitopes on 
the virion, resulting in incomplete coverage of the viral particle. Fig. 33A shows the 
contrast in accessibility on a mature virion for a non-neutralizing ZV2 antibody epitope (in 
green) and a neutralizing ZV67 antibody epitope (in pink). The incomplete binding of non-
neutralizing antibodies to the virion through these restricted cryptic epitopes, results in 
 
Figure 33. Accessibility of ZIKV DIII epitopes. (A) Mapping of the three distinct 
ZIKV DIII epitopes on the mature virion; neutralizing lateral-ridge epitopes are 
highlighted in magenta (B) Docking of ZV67 Fab on E protein dimer. Figure 




antibody-dependent enhancement (ADE) i.e., increased infection of host cells [120, 121]. 
ADE occurs following the binding of fewer antibody molecules to virions that is required 
for neutralizing infection; the bound antibodies then promote viral uptake phagocytic cells, 
thereby promoting infection [122].  
Furthermore, the immunodominance of non-neutralizing regions of DIII may result in 
lower than expected neutralizing antibody titers [123, 124]. In immunization studies of 
mice and non-human primates with DIII-based vaccines for Dengue Virus, although a 
robust antibody response was elicited against DIII, neutralization was modest [125-127], 
possibly  due to the presence of non-neutralizing antibodies [128, 129]. Hence, engineering 
DIII variants to shield the non-neutralizing epitopes and refocus the immune response on 
the neutralizing epitopes should result in more effective DIII-based flaviviral vaccines.  
One approach to address this shortcoming, has been explored by Frei et al. [130] for 
Dengue Virus DIII domains. Frei et al. [130] engineered the DIII domain for Dengue Virus 
(DENV) to suppress the elicitation of undesirable non-neutralizing antibodies. Their 
strategy involved “resurfacing” DIII (rsDIII) in which epitopes targeted by a broadly 
neutralizing anti-DENV antibody 4E11 was maintained, but less desirable epitopes (non-
neutralizing or serotype-specific) were masked by mutation. Although, one of their 
designed rsDIII (rsDIII-Ala30) showed decreased binding to non-neutralizing antibodies – 
upon immunization, the resulting sera failed to protect mice from a lethal DENV-2 
challenge [130]. A possible reason for this failure could be the incomplete suppression of 
the elicitation of undesirable antibodies by the “resurfacing” approach. A single residue 
mutation may be efficient at disrupting binding of a particular non-neutralizing antibody; 
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but other regions of the “non-neutralizing” patch would still be left exposed. Hence, 
strategies that more completely shield the non-neutralizing epitopes are required. 
To that end, we have developed an approach that attempts to suppress the elicitation of 
non-neutralizing antibodies more completely. Our strategy involves the use of antibody 
fragments to achieve this shielding. When the DIII domain is bound to a non-neutralizing 
Fab, the non-neutralizing epitope is essentially shielded completely. When this antigen-
Fab complex is presented as an immunogen, because of antigenic suppression [62], the 
antibody response to the cognate antigenic site (non-neutralizing epitope, in this case) 
should be suppressed. However, the binding of the Fab to the antigen is non-covalent, 
which may result in the complex falling apart upon immunization. To address this concern, 
our strategy involves tethering the DIII antigen to the non-neutralizing Fab by expression 
of the complex as a fusion protein, spaced by an appropriate linker.   
4.2 Materials and Methods 
4.2.1 Antigen expression and purification 
The DNA encoding light and heavy chain variable regions (VL and VH resp.) for ZIKV E 
DIII specific antibodies – ZV2 (PDB ID: 5KVD), ZV48 (PDB ID: 5KVE), and ZV67 (PDB 
ID: 5KVG), and a control antibody not specific to ZIKV E DIII – C179 (PDB ID: 4HLZ) 
– were optimized for mammalian expression and synthesized and cloned in the TGEX-LC, 
TGEX-FH and TGEX-HC vectors by Gene Universal Inc. (Newark, DE). Further, the 
DNA encoding DIII (PDB ID: 5KVG Chain E) optimized for mammalian expression was 
synthesized by Gene Universal Inc. and cloned upstream of the VL regions in TGEX-LC 
vectors for ZV2, ZV67 and C179 spaced by 3x repeats of GGGGS flexible linkers. A hexa-
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histidine tag was incorporated at the C-terminus of the heavy chain of all Fabs for 
purification purposes. 
To express the Fab-tethered DIII antigens, the plasmids for LC (DIII fused to the light 
chain of the Fab) and its partner FH were transfected in HEK293F suspension cells using 
the ExpiFectamine™ 293 transfection kit (A14524, Gibco) using manufacturer’s protocol. 
After expression, the cell culture supernatants were thoroughly dialyzed against PBS and 
Fabs were purified by IMAC followed by SEC on a Superdex 75 Increase 10/300 GL 
column (GE Healthcare, 29-1487-21) in PBS buffer. The SEC refining step removes 
aggregates if any. The purified Fab-tethered antigens were concentrated, quantified using 
BCA assay, and stored at 4°C until further use. 
A c-myc tag was inserted at the C-terminus of the heavy chains of Fabs ZV2, ZV48 and 
ZV67 and the Fabs were similarly expressed in 293F cells and purified via IMAC followed 
by a refinement SEC step as described above. 
Antibodies ZV2, ZV48, and ZV67 were similarly expressed in 293F cells and purified 
using the HiTrap MabSure Select™ column (29-0491-04, GE Healthcare) on an AKTA 
Start system following the manufacturer’s protocol. The antibodies (ZV2, ZV48, and 
ZV67) were further labelled with biotin for ELISA characterization purposes using EZ-
Link™ Sulfo-NHS-LC-Biotin (A39257, Thermo Scientific) following the manufacturer’s 
recommendations. 
4.2.2 Characterization of antigens by ELISA and analytical SEC 
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The designed antigens were characterized by ELISA to confirm the ability to block 
recognition to desired regions. Briefly, 50 µL of 0.002 mg/mL antigen solution (on a DIII 
basis) was coated per well on a 96-well Ni+2 coated ELISA plates (15442, Thermo 
Scientific) overnight at 4°C in PBS. After 3x washes with PBST, plates were incubated 
with 50 µL of primary antibody solutions (biotinylated antibodies ZV2 and ZV67) in 1% 
BSA in PBST for 1 hr at RT. After 3x washes with PBST plates were incubated with 
Streptavidin-HRP conjugated secondary antibody for 1 hr at RT. After 3x washes with 
PBST plates were developed with TMB substrate solution (00-2023, Thermo Fisher) for 5 
min and stopped using 160 mM sulphuric acid solution. Plates were read on a Spectramax 
i3x plate reader (Molecular devices) at 450 nm. Experiments were performed in triplicates. 
SEC shifts were performed with the Fab-tethered antigens by competing with the 
corresponding monomeric Fabs. All SEC chromatograms were run on Superdex 75 
Increase 10/300 GL column (GE Healthcare, 29-1487-21) in PBS buffer using 5ug of 
antigen (on a DIII basis). Competing and non-competing Fabs were run with the antigen in 
a 1.2:1 stoichiometric ratio with the monomeric Fab in excess. Chromatograms were 
recorded using UV280 or UV 205 and overlaid for comparison. 
4.2.3 Immunizations in mice 
The engineered Fab-tethered DIII mutants were immunized in BALB/c mice at the Florian 
Krammer Lab (Icahn School of Medicine at Mount Sinai, NY). Samples included were: (i) 
DIII-linker-ZV2Fab (Mutant 1), (ii) DIII-linker-ZV67Fab (Mutant 2), (iii) DIII-linker-
C179Fab (Mutant 3) and, (iv) PBS control.  Five mice were immunized per group. The 
protein antigens were diluted to 40 µg/mL in PBS (on a DIII basis). Two µg of antigen per 
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mouse was injected adjuvanted with poly I:C on days 0, 27, 54, 99. On day 115 the mice 
were terminally bled and serum was stored at -20°C until further use.  
4.2.4 Serum analysis 
The terminal bleed serum from all groups was assessed for endpoint titer against bacterially 
expressed wtDIII. Briefly, 50 µL of 0.002 mg/mL DIII was coated per well on ELISA 
plates overnight at 4°C in PBS. Plates were blocked with 100 µL of 5% BSA in PBST for 
1 hr at RT. After 3x washes with PBST plates were incubated with 50 µL of sera diluted 
four-fold starting at 1:100 in 1% BSA in PBST for 1 hr at RT. After 3x washes with PBST 
plates were incubated with a secondary HRP conjugated anti-mouse antibody (115-035-
003, Jackson ImmunoResearch) for 1 hr at RT. After 3x washes with PBST plates were 
developed with TMB substrate solution (00-2023, Thermo Fisher) for 5 min and stopped 
using 160 mM sulphuric acid solution. Plates were read on a Spectramax i3x plate reader 
(Molecular devices) at 450 nm. Titers were expressed as area under the curve (AUC) 
determined using GraphPad Prism software. Appropriate controls were included.  
The DNA encoding DIII was also optimized for bacterial expression, synthesized and 
cloned in pET28b vector between NdeI/XhoI sites with a C-terminal hexahistidine tag by 
Gene Universal Inc., Newark, DE. wtDIII protein was expressed in BL21(DE3) E. coli and 
purified from inclusion bodies as previously described [131]  
We generated Mut-N*, a variant of DIII with F* introduced at residues 353 (T353F*) and 
397 (T397F*).  This mutant was further doubly PEGylated using PEG5k-DBCO to 
generate Mut-N*-PEG. This PEGylated mutant of DIII shields regions on DIII other than 
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the non-neutralizing ZV2 face using PEG shields (as opposed to a Fab shield). The 
PEGylation and following separation was carried out as described in Chapter 2.  
4.2.5 Statistical analysis 
AUC was calculated using sigmoidal curve fitting. A minimum of three technical repeats 
were tested for all ELISAs, and the experiments were repeated at least three times with 
similar results. One-way ANOVA with post-hoc Tukey’s multiple comparison test was 
applied when indicated in the figure legend. All statistical analysis was performed using 
GraphPad Prism 8 (GraphPad Software Inc.) 
4.3 Results and Discussion 
4.3.1 Design, expression and purification of Fab-tethered DIII antigens 
Our approach to engineering DIII, to refocus the immune response towards the neutralizing 
lateral ridge epitopes (ZV67), involves tethering a Fab to DIII. Depending on the specificity 
of the Fab tethered to DIII, one can selectively shield an epitope of interest while exposing 
other regions on DIII. We wanted to suppress the elicitation of non-neutralizing antibodies 
upon immunizing with DIII. To achieve this, we designed a mutant of DIII tethered to the 
non-neutralizing Fab ZV2. The non-neutralizing Fab ZV2 when tethered to DIII, would 
effectively shield the non-neutralizing epitope of DIII, suppressing the elicitation of non-
neutralizing anti-DIII antibodies. This would allow refocusing of the immune response to 
the neutralizing lateral ridge epitopes.  
Fig. 34A shows the co-crystal structure of DIII (blue) bound to the non-neutralizing ZV2 
Fab (green) (PDB ID: 5KVD). In red are highlighted the C-terminus of DIII and the N-
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terminus of the light chain of the Fab. To tether the Fab to DIII, we chose to co-express the 
two proteins as a fusion protein spaced by repeats of a flexible GGGGS spacer. The crystal 
structure guided us in determining the appropriate length of the linker required to span the 
distance between the DIII and Fab (shown by the red residues in Fig 34A). In this case, the 
 
Figure 34. Design of Fab-tethered DIII mutants. (A) Crystal structure of DIII 
bound to the non-neutralizing Fab ZV2 (PDB ID: 5KVD) with the N-terminus of the 
light chain of ZV2 Fab and the C-terminus of DIII marked in red. (B) Cloning 
strategy for the design of Fab-tethered DIII mutants (C) Cartoons showing DIII-
tethered Fab mutants – Mut1 (non-neutralizing Fab in green), Mut2 (neutralizing Fab 
in pink) and Mut3 (non-DIII binding Fab in gray). DIII is shown in blue with the 




distance to span was ~ 3.5 nm. Coincidentally, this distance is similar to the distance 
between the VH and VL domain for an scFv – for which 3 repeats of GGGGS is most 
commonly used [132, 133]. Hence, we chose to use 3x repeats of GGGGS linker to space 
DIII and the Fab. The light chain of the Fab was more appropriate to fuse to DIII than the 
heavy chain based on its proximity to the C-terminus of DIII. Fig 34B shows the cloning 
strategy based on our analysis, where the DNA encoding DIII was fused upstream of the 
DNA encoding the ZV2 Fab LC spaced by the DNA for the linker. Fig 34C shows the 
cartoon for the designed DIII mutants. DIII in each case is shown in blue, with the non-
neutralizing epitopes marked in green and the neutralizing epitopes marked in magenta 
[115]. Mut1 is the mutant of interest where the DIII is tethered to the non-neutralizing Fab 
ZV2 (shown in green). This linker is represented by the squiggly green line. Mut2 is a 
control mutant that was designed to shield the neutralizing epitope (residues marked in 
pink), by tethering the neutralizing Fab (ZV67, shown in pink) to DIII. Thirdly, we also 
designed a Mut3 of DIII, wherein the DIII was tethered to a Fab that is not specific to DIII 
– effectively serving as a wt-like control. An Influenza Hemagglutinin binding Fab C179 
(PDB ID: 4HLZ) [134] was used for this purpose (shown in gray in Fig. 34C). 
4.3.2 Characterization of Fab-tethered DIII by SDS-PAGE and ELISA 
Fig. 35A shows an SDS-PAGE image of the designed Fab-tethered DIII mutants. All three 
mutants run on SDS-PAGE at ~65 kDa as expected. The MW for the DIII domain alone is 
~15kDa and for a Fab is ~50kDa. This result confirms the successful co-expression of DIII 
fused to each of the three Fabs. 
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Next we wanted to confirm if the specificity of the Fab tethered to DIII affects the binding 
of antibodies to DIII. In other words, we wanted to confirm if the non-neutralizing Fab 
tethered to DIII (Mut1) selectively blocks recognition of the non-neutralizing (ZV2) Ab, 
while retaining binding to the neutralizing (ZV67) Ab. Fig. 35B shows the ELISA result 
showing binding of the non-neutralizing Ab (ZV2) in green and of the neutralizing Ab 
 
Figure 35. Characterization of Fab-tethered DIII mutants. (A) SDS-PAGE image 
showing the ladder and the three DIII mutants (B) ELISA result comparing binding of 
the neutralizing Ab (pink) and non-neutralizing Ab (green) to the DIII mutants. 
ELISA binding expressed as absorbance (mean ± SD, n=3). (****p<0.0001, 





(ZV67) in pink, to the designed DIII mutants. As expected, Mut1 does not bind to the non-
neutralizing Ab (ZV2) but is recognized by the neutralizing Ab (ZV67). In contrast, Mut2 
does not bind to the neutralizing Ab (ZV67) but is recognized by the non-neutralizing Ab 
(ZV2), as expected. Mut3 binds to both antibodies, as expected. This result confirms the 
ability of a Fab shield tethered to an antigen to selectively block antibody recognition to 
desired regions. 
Next, we wanted to test if this selective suppression of antibody recognition also holds true 
in solution, which is a more realistic and more stringent test for our approach. We therefore 
performed competitive analytical SEC shifts. A protein will run on SEC and show a unique 
peak on the chromatogram corresponding to its size and shape. As a rule of thumb, as the 
protein or protein complex becomes larger, its peak on the chromatogram will shift to the 
left. We used this analytical SEC assay to confirm the ability of our engineered DIII 
mutants to either bind to or not bind to a Fab.  
Fig. 36A shows an overlay of chromatograms for SEC runs involving Mut1 competed with 
a stoichiometric amount of monomeric soluble untethered ZV2 Fab (shown on far right). 
The blue chromatogram corresponds to the monomeric ZV2 Fab alone. The chromatogram 
for Mut1, which is DIII fused to the ZV2 Fab, is shown in orange. As expected, the peak 
shifts to the left because of the added protein mass from DIII when compared to the ZV2 
Fab alone. In yellow is the chromatogram for Mut1 complexed with a stoichiometric 
amount of the neutralizing ZV67 Fab. The peak shifts further to the left when compared to 
the peak for Mut1 indicating that the Mut1 binds to the neutralizing ZV67 Fab. In addition, 
this also locates for us what a DIII-tethered mutant would look like if an additional Fab 
bound to it on the DIII domain. Next, to test if tethering the Fab to DIII prevents binding 
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of a competing monomeric Fab, we ran a complex of Mut1 with a stoichiometric amount 
of free ZV2 Fab. This chromatogram is shown in gray. Interestingly, the peak for this 
sample does not shift to the left (as for the yellow chromatogram), suggesting that the ZV2 
 
Figure 36. Characterization of Fab-tethered DIII mutants by analytical SEC. (A) 
Overlaid SEC chromatograms for Mut1 (orange), ZV2 Fab (blue), Mut1 complexed 
with ZV2 Fab (gray) and Mut1 complexed with ZV67 Fab (yellow) (B) Overlaid SEC 
chromatograms for Mut2 (orange), ZV67 Fab (blue), Mut2 complexed with ZV67 Fab 




Fab tethered to DIII prevents binding of competing ZV2 Fab in solution – and hence 
confirms the ability of tethering a Fab to an antigen as a way to suppress binding of 
antibodies to a desired epitope.  
Fig. 36B similarly shows the results for Mut2. The blue chromatogram shows the 
monomeric ZV67 Fab alone. The chromatogram for Mut2 (DIII tethered to ZV67 Fab) is 
shown in orange. As for Mut1, a mixture of Mut2 and ZV67 Fab does not shift to the left 
and in fact shows discrete peaks for Mut2 and ZV67 Fab. This result suggests that Mut2 
prevents binding of competing ZV67 Fab. As a reference, the yellow chromatogram shows 
that Mut2 does bind to the non-neutralizing ZV2 Fab as indicated by the leftward shift of 
the peak from ~10.9 mL to ~9.8 mL. 
4.3.3 Fab-tethering refocuses the immune response on DIII 
Next, to test the ability of Fab-tethered DIII to refocus the immune response away from 
undesirable epitopes in vivo, we immunized mice with our engineered DIII antigens (Mut1, 
Mut2, Mut3) and a PBS alone control. Fig. 37A shows the immunization schedule for the 
animal study. Fig. 37B shows the serum antibody titers for day 115 terminal bleed sera 
against wtDIII determined using the area under the curve (AUC) analysis method [62]. The 
titers for Mut3 were somewhat lower than those for Mut1 or Mut2. This result was not 
expected and one possible explanation could be the relatively higher protein stability for 
Mut1 and Mut2 by the binding of the DIII-specific Fabs to DIII when compared to Mut3 
which was fused to a non-DIII specific Fab. 
Next we wanted to probe if the specificity of the elicited antibodies elicited by the two 
mutants of interest – Mut1 and Mut 2, was different. In other words, we wanted to 
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determine if Mut1 elicited fewer antibodies binding to the non-neutralizing regions, when 
compared to Mut2. Fig. 38A shows a cartoon with the hypothesized immune response 
resulting from Mut1, Mut2, and Mut3. Mut1 should preferentially elicit neutralizing 
antibodies (shown in pink), whereas Mut2 should preferentially elicit non-neutralizing 
antibodies (shown in green). Mut3 (which is essentially a wtDIII equivalent) should elicit 
both neutralizing and non-neutralizing antibodies. To determine if this is true, we designed 
a mutant of DIII (using the nanopatterning approach discussed in Chapter 1), referred to as 
Mut-N*-PEG, the neutralizing (N) epitope of which is shielded by the site-specific 
conjugation of PEG chains to DIII. We incorporated the non-canonical amino acid F* at 
sites T353 and T397 and expressed the mutant protein DIII – referred to as Mut-N* (to 
indicate mutations inserted in the neutralizing epitope regions). We then allowed the 
mutant protein Mut-N* to react with PEG5k-DBCO and purified the PEGylated protein 
Mut-N*-PEG.  
 
Figure 37. Immunizations of Fab-tethered DIII mutants. (A) Immunization 
schedule in mice (B) Terminal bleed antibody serum titers for the three mutants and 




Fig. 38B shows the ELISA results for the binding of the terminal bleed serum for Mut1 
(pink bars), Mut2 (green bars), and Mut3 (blue bars) to wt DIII (left cluster) and to Mut-
 
Figure 38. Fab-tethered DIII mutants refocus the immune response. (A) 
Hypothesized immune response for Mut1 and Mut2. Mut1 should preferentially elicit 
neutralizing antibodies (pink) whereas Mut2 should preferentially elicit non-
neutralizing antibodies (green). (B) ELISA showing binding of terminal bleed serum 
for Mut1 and Mut2 to either wtDIII or to Mut-N*-PEG (neutralizing epitope of DIII 
shielded using PEG). ELISA binding expressed as absorbance (mean ± SD, n=3). 
(****p<0.0001, ns – not statistically significant, determined by a one-way ANOVA 





N*-PEG (right cluster). The gray bars show the background signal. A serum dilution of 
1:1000 was used for Mut1 and Mut2 and a dilution of 1:300 was used for Mut3 to normalize 
for the differences in titers. As can be seen, the binding for Mut1 serum drops to a larger 
extent when probed against the two antigens (wtDIII or Mut-N*-PEG), when compared to 
the drop in binding for Mut2 and Mut3 serum to the two antigens. Mut-N*-PEG has the 
neutralizing epitopes shielded, allowing only the non-neutralizing-like antibodies to bind. 
The signal for Mut1 serum when probed against Mut-N*-PEG is lower than that for Mut2 
serum. This result suggests that there is a smaller proportion of non-neutralizing-like 
antibodies in Mut1 as compared to that for Mut2 or Mut3. The signal from the binding of 
Mut3 serum to Mut-N*-PEG is lower than that for Mut2 serum but higher than that for 
Mut1 serum. In other words, this data suggests that, as expected, the proportion of non-
neutralizing-like antibodies in the serum is in the following order: Mut2 (neutralizing 
epitope shielded) > Mut3 (wild-type equivalent) > Mut1 (non-neutralizing epitope 
shielded).  
This data suggests that tethering antibody fragments to the antigen can selectively suppress 
the resulting immune response of the cognate antigenic epitope for DIII. Based on 
promising these preliminary results, as a part of future work, we will perform 
microneutralization assays to evaluate the functional benefit of selectively suppressing the 
elicitation of non-neutralizing antibodies for ZIKV E DIII. 
4.4 Conclusion and Future work 
DIII of E protein is a promising vaccine candidate for a ZIKA virus vaccine. However, 
the neutralization potential of DIII is limited because of the presence of undesirable non-
neutralizing antibodies. Our work presents an approach to selectively suppress the 
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elicitation of such undesirable antibodies elicited by DIII. We have used antibody 
fragments as shielding agents to mask the non-neutralizing epitopes from the immune 
system. We have shown that by tethering the non-neutralizing Fab to DIII, we can 
suppress the elicitation of non-neutralizing antibodies. As a part of future work, we will 
further characterize the serum from the engineered DIII mutants discussed in this chapter, 
by microneutralization assay. This assay will allow us to verify the functional benefit of 
suppressing the elicitation of non-neutralizing anti-DIII antibodies.  
The approach discussed in this section can be also extended to the design of other 
flaviviral DIII-based vaccines. For example, DIII from Dengue virus similarly elicits 
non-neutralizing antibodies limiting the broadly neutralizing antibody response and the 
potential of DIII as an effective immunogen. Non-neutralizing and serotype-specific Fabs 
have been characterized for DENV DIII [135, 136] allowing our approach to be easily 
extended to design DENV DIII based vaccines that selectively elicit neutralizing 
antibodies.  Further, the approach of using antibody fragments as shielding agents can be 
used to design vaccines for other infectious diseases as well, refocusing the response to 
the broadly conserved regions of their antigens.   
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CHAPTER 5. CONCLUSION AND FUTURE DIRECTIONS 
 
In the current work we have developed tools to engineer protein antigens to selectively 
shield regions of the protein to focus the immune response on other regions. Vaccine 
development suffers from the high antigenic sequence variability on the surface proteins 
of pathogens. However, there are often conserved regions on pathogenic proteins that are 
naturally immunosubdominant. Hence, strategies to selectively shield the 
immunodominant variable regions of these protein antigens to refocus the immune 
response on the more conserved regions is a useful tool to design broadly protective 
vaccines. 
We have developed two tools to achieve immunofocusing on protein antigens in the current 
work. The first termed as “Nanopatterning” involves the site-specific conjugation of 
polymeric chains to targeted regions of the protein antigen with the goal of suppressing the 
immune response to that defined region. We have used GFP as a model antigen, and 
nanopatterned a defined epitope for a GFP Nanobody. We have shown the selective 
suppression of the immune response to the Nanobody epitope by nanopatterning GFP. 
Next, we extended the nanopatterning idea to an important malarial antigen – MSP119 and 
showed the ability to refocus the response to a conserved inhibitory epitope. 
Nanopatterning MSP119 allowed the detection of MSP119 from a highly divergent 
heterologous strain that differs at as many as 21 of 96 residues.  
Nanopatterning allows a much finer control over blocking of selected regions by the site-
specific attachment of a defined length of a polymeric chain to a protein. This approach is 
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in contrast to the traditional multiple and random PEGylation of proteins to suppress the 
global immune response of therapeutic proteins. This approach can be extended to other 
antigens to elicit broadly protective antibodies. One can use polymers other than PEG and 
also use different chemistries by the incorporation of multiple non-canonical amino acids 
to allow a much finer control over shielding. Further, these nanopatterned proteins could 
also be used for diagnostics applications to screen for a particular class of antibodies based 
on where it binds on the antigen.  
Having shown the successful refocusing of the immune response of PyMSP119 to the 
conserved epitopes, we are next assessing the functional benefit of the refocusing by 
evaluating binding of the serum antibodies to a parasite from a heterologous strain by an 
Immunoflourescence assay (IFA). Similarly for PfMSP119, it would be interesting to 
evaluate the ability of refocusing the immune response to protect mice in a passive 
immunoprophylaxis model on challenging with a transgenic P.berghei parasite [137]. 
Further, our lab has already started to work on nanopatterning another important malarial 
antigen – Pf circumsporozoite protein (PfCSP), which the current vaccine candidate 
RTS,S/A01 is based on. The nanopatterning approach should allow refocusing of the 
immune response to broadly neutralizing epitopes of PfCSP that are not included in the 
RTS,S/A01 vaccine. 
We have also developed a second approach that uses antibody fragments (Fabs) as 
shielding agents. We have developed two related approaches using Fabs as shields – one 
that involves tethering the Fab to the antigen and a second approach that involves designing 
multivalent Fabs as shielding agents. We have shown that the tethering approach allows 
refocusing of the immune response to desired regions of an antigen for Hemagglutinin 
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(HA) from influenza virus and the Domain III (DIII) of the envelope protein of Zika virus. 
Tethered-Fab shields were explored to refocus the immune response to the broadly 
conserved stalk domain of HA and to suppress the elicitation of non-neutralizing antibodies 
for DIII. We have similarly shown an alternative approach to shielding the undesirable 
head domain of HA by using bivalent Fabs as shields.  
As a part of future work, we will test the functional ability of the immune refocusing 
achieved for these antigens (HA and DIII) in microneutralization assays. It would also be 
interesting to test these Fab-shielded HA vaccine constructs in a mouse model with pre-
existing immunity to influenza virus to better probe the advantage of shielding over wtHA 
control. We also plan to extend the approach to H3 HA from group II of the influenza virus, 
as a part of future work. Similarly, we plan to extend our findings from the ZIKV EDIII 
work to design a Dengue Virus vaccine in the near future. Also, this idea can be extended 
to other antigens, for example the Fusion protein from RSV, to elicit broadly protective 
anti-RSV antibodies or to design vaccines against other flaviviruses.  
Fabs are advantageous as shielding agents because they selectively bind to a region on an 
antigen and in effect shield it. Fabs are also considered largely non-foreign by our immune 
systems – and in using them as shielding agents, their most “immunogenic” regions 
(CDRs) are shielded by the antigen it binds to. The current work also discusses a strategy 
to design a bivalent Fab that may be used for applications other than protein shielding or 
vaccine design. We have already extended the approach discussed in this work to design 
bivalent Fab-based agonists of the Wnt signalling pathway. 
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Antigenic sequence variability has stalled vaccine progress for several otherwise highly 
immunogenic proteins, as the ones discussed in this work. The tools discussed in this work 
can be applied to immunogens from other infectious diseases. The approach involving Fabs 
as shielding agents can most easily be translated to a commercial setting. Antibodies and 
antibody-like molecules have been extensively studied and developed by the 
pharmaceutical industry, making commercialization of a Fab-shielded antigen a 
possibility. Similarly, several PEGylated therapeutic proteins are already in the clinic, 
making the nanopatterning approach adaptable to an industrial setting. 
The tools developed in this work have their pros and cons, as for the existing approaches 
to immunofocusing. It is important to highlight some of the limitations of the approaches 
discussed. For example, the nanopatterning approach involves the incorporation of non-
canonical amino acids which may affect protein folding and stability, and may be 
expensive to implement. Additionally, the use of this approach is relatively difficult to 
apply to a protein expressed in insect cell system (e.g. HA), for which the ncAA 
incorporation machinery is less developed than for bacterial or mammalian protein 
expression systems. 
One important limitation in using Fabs (or other ligands) as shielding agents is the 
availability of a characterized antibody that binds to the region one wishes to shield. In the 
absence of any known antibody or ligand that has been structurally characterized to bind 
to the desired antigen epitope, the Fab-based approach cannot be applied. The tethering 
approach may require some modification of the antigen (e.g. as in case of HA), that may 
limit its application. The multivalent-Fab approach requires the availability of Fabs (or 
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other ligands) that bind to different regions of the antigen; – the absence of suitable ligands 
would limit the use of this approach. 
Despite their limitations, the strategies developed and discussed in this thesis add to the 
existing, but limited toolkit of immunofocusing. The tools developed in this work can 
counter immune evasion strategies developed in pathogens and accelerate progress of 
vaccine research. The development of several potential vaccine candidates is impeded by 
challenges such as high antigenic sequence variability – which can be addressed by the 
proposed tools. This work lays the foundation for the design of broadly protective vaccines 
for Malaria, Influenza, and Zika. We have shown the applicability of our approaches for 
antigens from these three medically highly relevant diseases. The tools developed in this 
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